Gregory Pond - McMaster Experts

Affiliations

Faculty of Health Sciences, McMaster University
Full-Time Member, Escarpment Cancer Research Institute (ECRI), Faculty of Health Sciences
Associate Member, Health Research Methods, Evidence, and Impact, Faculty of Health Sciences
Professor, Oncology, Faculty of Health Sciences
Associate Member, Mathematics and Statistics, Faculty of Science

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Research
Contact
View All

selected scholarly activity

chapters
- Essential Statistical Tests. 1703-1716. 2022
- Essential Statistical Tests. 1-14. 2020
- Types of Variables and Distributions. 23-35. 2018
conferences
- Incidence of venous thromboembolism in newly diagnosed glioblastoma multi-forme and associated risk factors: A retrospective chart review. Journal of Clinical Oncology. 2024
- Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada. Journal of immunotherapy (Hagerstown, Md. : 1997). 123-127. 2024
- SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 2220-2225. 2023
- Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR plus breast cancer in the TEAM trial.. Journal of Clinical Oncology. 2023
- Can synthetic data accurately mimic oncology clinical trials?. Journal of Clinical Oncology. 2023
- Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.. Journal of Clinical Oncology. 2023
- Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach. Journal of Clinical Oncology. 2023
- Multisystem immune-related adverse events from dual agent immunotherapy use. Journal of Clinical Oncology. 2023
- Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.. Journal of Clinical Oncology. 2023
- Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study. Journal of Clinical Oncology. 2023
- A patient survey evaluating COVID-19-induced changes in follow-up of patients with EBC: opportunities for enhanced evidence-based practice?. Breast. S127-S127. 2023
- A pragmatic randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy for early breast cancer (REaCT-CHRONO Study). Breast. S24-S25. 2023
- Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers. Breast. S132-S132. 2023
- Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada. Blood. 427-429. 2022
- Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL). Blood. 2395-2396. 2022
- 545 A phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 (cisplatin, vinblastine) in early stage breast cancer: the INVINCIBLE trial. Journal for ImmunoTherapy of Cancer. A570-A570. 2022
- A randomized controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairment. Asia-Pacific Journal of Clinical Oncology. 99-99. 2022
- 2022-RA-744-ESGO Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative. Miscellaneous. a189.1-a1a189. 2022
- Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.. Journal of Clinical Oncology. 332-332. 2022
- Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada. Journal of Thoracic Oncology. S124-S124. 2022
- INCIDENCE AND MANAGEMENT TRENDS IN LOCALLY ADVANCED HEAD AND NECK NON-MELANOMA SKIN CANCER. Radiotherapy and Oncology. S32-S32. 2022
- OUTCOMES OF RADIOTHERAPY ALONE FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC) IN PATIENTS UNFIT FOR CHEMO-RADIOTHERAPY. Radiotherapy and Oncology. S39-S39. 2022
- RADIATION DOSE, TECHNIQUE, AND USE OF BRAIN RADIATION ON OVERALL SURVIVAL IN PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER. Radiotherapy and Oncology. S31-S31. 2022
- RADIOTHERAPY DOSE, FDG-PET UTILIZATION AND SURVIVAL OUTCOMES OF UNRESECTED LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC). ONTARIO POPULATION OUTCOMES OF CONTEMPORARY RADIOTHERAPY ALONE AND STANDARD OF CARE CHEMO-RADIOTHERAPY. Radiotherapy and Oncology. S59-S60. 2022
- THE EVOLUTION OF TECHNOLOGY IN THE MANAGEMENT OF EARLY-STAGE (T1) CANCER OF THE LARYNX, AN INSTITUTIONAL REVIEW OF RADIATION THERAPY OUTCOMES. Radiotherapy and Oncology. S74-S74. 2022
- OAB-042: The impact of marginalization on treatment receipt and overall survival in newly diagnosed multiple myeloma patients in Ontario: a population-based cohort study. Clinical Lymphoma, Myeloma and Leukemia. S25-S26. 2022
- The impact of marginalization on treatment receipt and overall survival in Newly Diagnosed Multiple Myeloma patients in Ontario: A Population-Based Cohort Study.. Clinical Lymphoma, Myeloma and Leukemia. S25-S26. 2022
- LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T₁N₀ luminal A breast cancer (BC).. Journal of Clinical Oncology. 2022
- Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.. Journal of Clinical Oncology. E18628-E18628. 2022
- Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).. Journal of Clinical Oncology. 2022
- Nivolumab in squamous cell carcinomas of the head and neck (SCCHN): A real-world outcome study in Ontario, Canada.. Journal of Clinical Oncology. e18017-e18017. 2022
- Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.. Journal of Clinical Oncology. 2022
- SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.. Journal of Clinical Oncology. 2022
- The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma. Journal of Clinical Oncology. 2022
- The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma.. Journal of Clinical Oncology. TPS12144-TPS12144. 2022
- Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?. Journal of Clinical Oncology. 2022
- Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 485-485. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS398-TPS398. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2022
- Is Symptom Burden Associated with Health Care Utilization: A Longitudinal Population-Based Cohort Study of Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood. 116-116. 2021
- EPV062/#354 Comparison of outcomes between abdominal, minimally invasive and combined vaginal- laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian cervical cancer collaborative) study. International Journal of Gynecological Cancer. A53-A54. 2021
- EPV063/#357 The impact of surgical approach in cases with no residual disease on hysterectomy specimen: a 4C (Canadian cervical cancer collaborative) working group study. International Journal of Gynecological Cancer. A54-A54. 2021
- OP005/#352 Safety of vaginal hysterectomy for cervical cancer: a multicenter cohort study on behalf of the 4C (Canadian cervical cancer collaborative) working group. International Journal of Gynecological Cancer. A13-A13. 2021
- The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario, Canada Between 2009-2017. International Journal of Radiation Oncology Biology Physics. e430-e430. 2021
- Extent of Surgical Resection in Inflammatory Bowel Disease Associated Colorectal Cancer: a Population-Based Study. Journal of Gastrointestinal Surgery. 2610-2618. 2021
- THE ROLE OF FDG-PET IN STAGING AND TREATMENT FOR STAGE III NSCLC IN ONTARIO BETWEEN 2009-2017. Radiotherapy and Oncology. S44-S44. 2021
- Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 453-453. 2021
- Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 432-432. 2021
- A physician survey evaluating real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast cancer. Cancer Research. 2021
- Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes. Blood. 30-31. 2020
- Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study. Blood. 1-2. 2020
- Cardiac Morbidity Following Radical Thoracic Chemoradiotherapy for Locally Advanced Lung Cancer: A Population-Based Cohort Study. International Journal of Radiation Oncology Biology Physics. e115-e116. 2020
- Randomized Phase II Trial of Metformin in Combination with Chemoradiotherapy (CRT) in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464). International Journal of Radiation Oncology Biology Physics. S104-S104. 2020
- Predictors of Minimally Invasive Surgery for Uterine and Cervix Cancer from 2000 – 2017 in Ontario, Canada. Gynecologic Oncology. 273-274. 2020
- Social determinants of health in uterine cancer patients in Ontario: Association with disease presentation and outcomes. Gynecologic Oncology. 66-66. 2020
- CARDIAC MORBIDITY FOLLOWING RADICAL THORACIC CHEMORADIOTHERAPY FOR LOCALLY ADVANCED LUNG CANCER: A POPULATION-BASED COHORT STUDY. Radiotherapy and Oncology. S90-S90. 2020
- DOSIMETRIC COMPARISON OF CONFORMAL RADIATION THERAPY (CRT), IMRT AND VMAT FOR ESOPHAGEAL CANCER TREATED WITH EXTERNAL RADIATION. Radiotherapy and Oncology. S35-S36. 2020
- A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.. Journal of Clinical Oncology. 2020
- Dissecting outcomes of patients (pts) with < ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.. Journal of Clinical Oncology. 2020
- Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 2020
- Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.. Journal of Clinical Oncology. 2020
- A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics. 985-992. 2020
- A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma. Journal of Clinical Oncology. 2020
- Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology. 2020
- Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors. Journal of Clinical Oncology. 2020
- FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2020
- FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 23-23. 2020
- Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy. Journal of Clinical Oncology. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS761-TPS761. 2020
- Abstract P4-10-29: Identifying novel molecular markers of response to trastuzumab in metastatic breast cancer. Cancer Research. 2020
- Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment. Blood. 4774-4774. 2019
- Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort. Blood. 268-268. 2019
- Conditional immune toxicity rate with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 2019
- EP618 The use of preoperative imaging in endometrial cancer: are ontario physicians following GOC guidelines?. International Journal of Gynecological Cancer. A362-A363. 2019
- GERIATRIC ASSESSMENT CHANGES IN OLDER PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING TREATMENT. Journal of Geriatric Oncology. S73-S74. 2019
- CYBERKNIFE STEREOTACTIC RADIOSURGERY FOR TREATMENT OF BENIGN INTRACRANIAL MENINGIOMA: LONG-TERM SAFETY AND EFFICACY. Radiotherapy and Oncology. S46-S47. 2019
- Quality of Life Assessment in Older Patients with Newly-Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. e232-e233. 2019
- A Comparison of Radiation Techniques in Patients Treated with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics. E526-E527. 2019
- Abstract CT122: Randomized assessment of cisplatin dose interval for ototoxicity in the treatment of locally advanced squamous cell carcinoma of the head and neck undergoing curative concurrent chemoradiotherapy (RADIO). Cancer Research. CT122-CT122. 2019
- Abstract CT122: Randomized assessment of cisplatin dose interval for ototoxicity in the treatment of locally advanced squamous cell carcinoma of the head and neck undergoing curative concurrent chemoradiotherapy (RADIO). Clinical Trials. ct122-ct122. 2019
- 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.. Journal of Clinical Oncology. 4552-4552. 2019
- A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid premedication for docetaxel chemotherapy.. Journal of Clinical Oncology. 6610-6610. 2019
- Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).. Journal of Clinical Oncology. 2019
- Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada.. Journal of Clinical Oncology. 6629-6629. 2019
- First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology. e16024-e16024. 2019
- The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement.. Journal of Clinical Oncology. e23142-e23142. 2019
- weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration resistant prostate cancer.. Journal of Clinical Oncology. 2019
- A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases. Annals of Oncology. 2019
- The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy.. Journal of Nuclear Medicine. 2019
- The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada. Journal of Geriatric Oncology. 449-458. 2019
- First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 432-432. 2019
- Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.. Journal of Clinical Oncology. 435-435. 2019
- Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology. 479-479. 2019
- PD-L1 in Breast Cancer: 3 Different Scoring Systems. Laboratory Investigation. 2019
- PD-L1 in Breast Cancer: 3 Different Scoring Systems. Modern Pathology. 2019
- Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.. Journal of Clinical Oncology. 476-476. 2019
- Increased Mortality in Younger Patients with Inflammatory Bowel Disease Associated Colorectal Cancer: A Population-Based Cohort Study. Annals of Surgical Oncology. S109-S109. 2019
- Oncologists and medical assistance in dying: Where do we stand?. Journal of Clinical Oncology. 64-64. 2018
- DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS. Neuro-Oncology. 234-235. 2018
- Does Modern Mediastinal Irradiation Cause Acute Subclinical Cardiac Toxicity? The Final Results of the MEDICATE Study (Mediastinal Irradiation and Cardio-Toxic Effects). International Journal of Radiation Oncology Biology Physics. S88-S89. 2018
- Outcomes of Tri-Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics. e89-e89. 2018
- Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials. International Journal of Radiation Oncology Biology Physics. S148-S148. 2018
- P2.11-23 Risk Perception Among a Lung Cancer Screening Population. Journal of Thoracic Oncology. S788-S788. 2018
- P2.15-31 The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014. Journal of Thoracic Oncology. S829-S830. 2018
- Improving quality of life for patients with breast cancer invading the chest wall: A prospective trial for patients undergoing full thickness chest wall resection. Annals of Surgical Oncology. 370-371. 2018
- Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.. Journal of Clinical Oncology. 5018-5018. 2018
- Clinical Significance of the AJCC 8th Edition Prognostic Staging System for Triple Negative Breast Cancer (TNBC). Modern Pathology. 51-52. 2018
- Clinical Significance of the AJCC 8th Edition Prognostic Staging System for Triple Negative Breast Cancer (TNBC). Laboratory Investigation. 51-52. 2018
- C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy.. Journal of Clinical Oncology. 436-436. 2018
- Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.. Journal of Clinical Oncology. 225-225. 2018
- New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. Journal of Clinical Oncology. 413-413. 2018
- Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.. Journal of Clinical Oncology. 451-451. 2018
- Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.. Journal of Clinical Oncology. 448-448. 2018
- Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi).. Journal of Clinical Oncology. 277-277. 2018
- Prognostic relevance of neutrophil-to-lymphocyte ratio (NLR) in young women with breast cancer (BC). Cancer Research. 2018
- Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years. Molecular Cancer Therapeutics. A100-A100. 2018
- MA 20.11 Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population. Journal of Thoracic Oncology. S1890-S1890. 2017
- A Phase 3, Multicenter, Randomized Trial to Evaluate the Symptomatic and Quality of Life Improvements in Lung Cancer Patients Receiving External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy. International Journal of Radiation Oncology Biology Physics. S116-S116. 2017
- Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population. Annals of Oncology. 2017
- Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.. Journal of Clinical Oncology. 4534-4534. 2017
- Neurocognitive functions and psychological distress in young adults with cancer (YAC): A prospective, longitudinal study.. Journal of Clinical Oncology. 10064-10064. 2017
- Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials.. Journal of Clinical Oncology. e16012-e16012. 2017
- Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review.. Journal of Clinical Oncology. e21064-e21064. 2017
- Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. Journal of Clinical Oncology. e16503-e16503. 2017
- Use of a marketing plan for recruitment to a lung cancer screening study.. Journal of Clinical Oncology. 1548-1548. 2017
- A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer. Annals of Oncology. 2017
- Prognostic classification of muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) alone or with perioperative chemotherapy: Analysis of the U.S. National Cancer Database (NCDB).. Journal of Clinical Oncology. 372-372. 2017
- Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab. Cancer Research. 2017
- MA05.06 Diagnosis of Chronic Obstructive Pulmonary Disease in Lung Cancer - A Population Based Study. Journal of Thoracic Oncology. S366-S367. 2017
- Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial. Annals of Oncology. vi335-vi335. 2016
- Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis. Annals of Oncology. vi291-vi291. 2016
- Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC). Annals of Oncology. vi285-vi285. 2016
- Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) – a validation study. Annals of Oncology. vi283-vi283. 2016
- The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology Biology Physics. E315-E315. 2016
- INDENTIFICATION OF CURCULATING MIRNA ASSOCIATED WITH DEVELOPMENT OF CASTRATE RESISTANCE IN HIGH-RISK AND BIOCHEMICALLY RECURRENT PROSTATE CANCER PATIENTS. Radiotherapy and Oncology. S52-S52. 2016
- PATHOLOGIC AND TREATMENT FACTORS ASSOCIATED WITH RECURRENCE IN STAGE IA SEROUS ADENOCARCINOMA OF THE UTERUS. Radiotherapy and Oncology. S83-S83. 2016
- Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI.. Journal of Clinical Oncology. 10097-10097. 2016
- Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer.. Journal of Clinical Oncology. e15126-e15126. 2016
- Suggested reclassification strategy applied to intermediate and poor risk nonseminomatous germ cell tumors (NSGCT): A two-institution combined analysis.. Journal of Clinical Oncology. 4546-4546. 2016
- Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.. Journal of Clinical Oncology. 5079-5079. 2016
- Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside. Journal of Thoracic Oncology. S91-S91. 2016
- Abstract P3-07-16: Comparing surrogates of oncotype Dx recurrence scores in invasive ductal carcinoma: How complicated does it have to be?. Cancer Research. 2016
- Comparing surrogates of oncotype Dx recurrence scores in invasive ductal carcinoma: How complicated does it have to be?. Cancer Research. 2016
- OCOG-ALMERA: A phase II trial investigating the ability of metformin to chemo-radio-sensitize and prevent recurrence in locally advanced (LA) non-small cell lung cancer (NSCLC)∗. Journal of Thoracic Oncology. S50-S51. 2016
- Targeting tumor metabolism to improve radio-sensitivity in non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. S50-S50. 2016
- Neurocognitive function and psychological distress in young adults (YA) with cancer.. Journal of Clinical Oncology. 199-199. 2016
- Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 386-386. 2016
- Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.. Journal of Clinical Oncology. 213-213. 2016
- Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 191-191. 2016
- Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors.. Journal of Clinical Oncology. 385-385. 2016
- A Phase 2 Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-field Boost Radiation Therapy for Brain Oligometastases. International Journal of Radiation Oncology Biology Physics. S39-S39. 2015
- OUTCOME OF NEUROFIBROMATOSIS TYPE 1 PATIENTS TREATED WITH FIRST LINE VINBLASTINE FOR OPTIC PATHWAY GLIOMAS (OPG): A CANADIAN MULTICENTER STUDY. Pediatric Blood and Cancer. S148-S148. 2015
- QUALITY OF LIFE IN CHILDREN WITH LOW-GRADE GLIOMA RECEIVING VINBLASTINE AS FIRST-LINE TREATMENT: A CANADIAN MULTICENTER STUDY. Pediatric Blood and Cancer. S277-S277. 2015
- Survival in Patients With Brain Metastases From Non-Small Cell Lung Cancer Treated in the Radiosurgery Era. International Journal of Radiation Oncology Biology Physics. E434-E435. 2015
- Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis. Annals of Oncology. 55-56. 2015
- A Phase II Study of Dovitinib in Previously-Treated Malignant Pleural Mesothelioma: The Ontario Clinical Oncology Group DOVE-M Trial. Journal of Thoracic Oncology. S352-S352. 2015
- Comparative Survival in Patients with Brain Metastases from Non-Small Cell Lung Cancer Treated before and after Implementation of Radiosurgery. Journal of Thoracic Oncology. S276-S276. 2015
- Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors.. Journal of Clinical Oncology. 2015
- Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC). Journal of Clinical Oncology. 2015
- Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 4527-4527. 2015
- Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis.. Journal of Clinical Oncology. e15526-e15526. 2015
- Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. e16095-e16095. 2015
- Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. Journal of Clinical Oncology. 2019-2019. 2015
- The role of PET-CT in treatment decision making for women with locally advanced cervical cancer.. Journal of Clinical Oncology. 5523-5523. 2015
- Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 5057-5057. 2015
- The Specimen Margin Assessment Technique (SMART) Trial: A Novel Method of Identifying the Most Accurate Method of Specimen Orientation in Breast Cancer Surgery. Annals of Surgical Oncology. 30-31. 2015
- Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 186-186. 2015
- Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.. Journal of Clinical Oncology. 335-335. 2015
- Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. Journal of Clinical Oncology. 311-311. 2015
- Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration.. Journal of Clinical Oncology. 2015
- INFLAMMATION AND COGNITION. Asia-Pacific Journal of Clinical Oncology. 91-92. 2014
- 205 Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancer. European Journal of Cancer. 67-67. 2014
- A Prospective Comparative Analysis of 3 Methods of Rectal Retraction for High-Dose-Rate Brachytherapy in Cervical Carcinoma: Effect on Organs at Risk. International Journal of Radiation Oncology Biology Physics. S476-S477. 2014
- A Retrospective Review of Patient Outcomes Following High-Dose-Rate Brachytherapy in the Treatment of Cervical Cancer. International Journal of Radiation Oncology Biology Physics. S489-S490. 2014
- Assessment of galectin-3, N-terminal pro-brain natriuretic peptide and inflammatory cytokines in patients with myocardial injury after initiation of adjuvant trastuzumab therapy. Clinical Biochemistry. 1144-1144. 2014
- ANTI-TUMOR ACTIVITY OF SELINEXOR (KPT-330), AN ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE), +/- DEXAMETHASONE IN MULTIPLE MYELOMA PRECLINICAL MODELS & TRANSLATION IN PATIENTS WITH MULTIPLE MYELOMA. Haematologica. 359-359. 2014
- A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 2537-2537. 2014
- A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas.. Journal of Clinical Oncology. 8551-8551. 2014
- Androgen pathway manipulation and outcome in elderly men with non-small cell lung cancer: A population-based study from Ontario, Canada.. Journal of Clinical Oncology. e17662-e17662. 2014
- Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study.. Journal of Clinical Oncology. e15616-e15616. 2014
- Do patients with small cell lung cancer (SCLC) who have chemotherapy initiated during a hospital admission benefit from therapy?. Journal of Clinical Oncology. e17661-e17661. 2014
- External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 4542-4542. 2014
- Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. Journal of Clinical Oncology. 4514-4514. 2014
- Using Magee equations to predict Oncotype DX recurrence scores: A potential cost and time saving strategy?. Journal of Clinical Oncology. e22109-e22109. 2014
- Increasing Utilization of Breast MRI: A Population Study. Annals of Surgical Oncology. 58-58. 2014
- Impact of Wait Times on Survival for Women With Uterine Cancer. Obstetrical and Gynecological Survey. 143-144. 2014
- Clinical-Pathologic Significance of Androgen Receptor (AR) Expression in Hormone Receptor (HR) Negative Breast Cancer. Modern Pathology. 48A-48A. 2014
- Clinical-Pathologic Significance of Androgen Receptor (AR) Expression in Hormone Receptor (HR) Negative Breast Cancer. Laboratory Investigation. 48A-48A. 2014
- Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. Journal of Clinical Oncology. 353-353. 2014
- Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. Journal of Clinical Oncology. 336-336. 2014
- Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis.. Journal of Clinical Oncology. 43-43. 2014
- Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.. Journal of Clinical Oncology. 482-482. 2014
- Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM). Blood. 2013
- Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML). Blood. 2013
- Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Blood. 90-90. 2013
- A LONGITUDINAL, PROSPECTIVE STUDY EVALUATING FATIGUE AND QUALITY OF LIFE IN COLORECTAL CANCER (CRC) PATIENTS. Asia-Pacific Journal of Clinical Oncology. 92-92. 2013
- ASSESSMENT OF HEALTH CARE PATTERNS FOR ELDERLY LUNG CANCER PATIENTS IN ONTARIO, CANADA. Journal of Thoracic Oncology. S403-S403. 2013
- WEEKLY VINBLASTINE IN CHEMOTHERAPY NAIVE CHILDREN AND ADOLESCENT WITH UNRESECTABLE OR PROGRESSIVE LOW GRADE GLIOMA: A CANADIAN COOPERATIVE STUDY. Neuro-Oncology. 165-166. 2013
- Abstract A124: Characterization of claudin-low breast cancers. Molecular Cancer Research. A124-A124. 2013
- The feasibility, acceptability and safety of Molecular Breast Imaging (MBI) using a breast specific gamma camera and 99mTc-sestamibi in patients with a high risk of breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. S462-S462. 2013
- Prognostic risk stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy. European Journal of Cancer. S647-S647. 2013
- WEEKLY VINBLASTINE IN CHEMOTHERAPY NAIVE CHILDREN WITH UNRESECTABLE OR PROGRESSIVE LOW GRADE GLIOMA: A CANADIAN COOPERATIVE STUDY. Pediatric Blood and Cancer. 19-19. 2013
- First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 2013
- Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.. Journal of Clinical Oncology. 2013
- Impact of wait times on survival of women with uterine cancer.. Journal of Clinical Oncology. 2013
- Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC). Journal of Clinical Oncology. 2013
- Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study-NCT00811369.. Journal of Clinical Oncology. 2013
- Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.. Journal of Clinical Oncology. 2013
- Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.. Journal of Clinical Oncology. e20522-e20522. 2013
- Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study. Journal of Clinical Oncology. 2013
- Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 301-301. 2013
- Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.. Journal of Clinical Oncology. 256-256. 2013
- Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 111-111. 2013
- Analytical Variables That Affect the Prognostic Utility of Ki67 in Invasive Breast Cancer. Modern Pathology. 74A-75A. 2013
- Analytical Variables That Affect the Prognostic Utility of Ki67 in Invasive Breast Cancer. Laboratory Investigation. 74A-75A. 2013
- Abstract P6-09-02: Pre-treatment cognitive function (CF) in women with locally advanced breast cancer (LABC) and in healthy controls.. Cancer Research. 2012
- ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER. Annals of Oncology. 297-298. 2012
- PROGNOSTIC STRATIFICATION OF ADVANCED UROTHELIAL CARCINOMA (UC) RECEIVING SECOND-LINE SYSTEMIC THERAPY INCLUDING TIME FROM PRIOR CHEMOTHERAPY (TFPC) AS A PROGNOSTIC FACTOR. Annals of Oncology. 265-266. 2012
- COGNITIVE FUNCTION AND FATIGUE IN COLORECTAL CANCER PATIENTS: A PROSPECTIVE, LONGITUDINAL CONTROLLED STUDY. Asia-Pacific Journal of Clinical Oncology. 46-46. 2012
- PATIENT FACTORS INVOLVED IN REFERRAL FOR LYNCH SYNDROME. Annals of Oncology. 91-91. 2012
- Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study. Journal of Clinical Oncology. 2012
- Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort. Journal of Clinical Oncology. 2012
- Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial. Journal of Clinical Oncology. 2012
- Quantitative immunohistochemical (IHC) assessment of ataxia-telangiectasia mutated (ATM) in estrogen receptor (ER) negative early breast cancer (BC).. Journal of Clinical Oncology. 2012
- Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.. Journal of Clinical Oncology. 2012
- Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors. European Journal of Cancer. S147-S147. 2012
- Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).. Journal of Clinical Oncology. 204-204. 2012
- Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 51-51. 2012
- Claudin-Low Breast Cancer; a Molecular Subtype Associated with Poor Prognosis. Modern Pathology. 34A-34A. 2012
- Claudin-Low Breast Cancer; a Molecular Subtype Associated with Poor Prognosis. Laboratory Investigation. 34A-34A. 2012
- Morphological Characteristics of HER2 Over-Expressing and Basal-Like Breast Cancers and the Association between Lymphocytic Tumor Infiltrate and Prognosis. Modern Pathology. 25A-25A. 2012
- Morphological Characteristics of HER2 Over-Expressing and Basal-Like Breast Cancers and the Association between Lymphocytic Tumor Infiltrate and Prognosis. Laboratory Investigation. 25A-25A. 2012
- P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity.. Cancer Research. 2011
- Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).. Molecular Cancer Therapeutics. A50-A50. 2011
- A PROSPECTIVE QUALITY ASSURANCE STUDY OF PROPER UTILIZATION OF METERED DOSE INHALERS IN THE MEDICAL INPATIENT POPULATION. Respirology. 3-4. 2011
- 1314 POSTER Quality of Reporting of Modern Randomized Controlled Trials in Oncology. European Journal of Cancer. S167-S167. 2011
- DO BETA-BLOCKERS ALTER DYSPNEA AND FATIGUE IN ADVANCED LUNG CANCER? A RETROSPECTIVE ANALYSIS. Journal of Thoracic Oncology. S1192-S1193. 2011
- A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer.. Journal of Clinical Oncology. 9020-9020. 2011
- Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).. Journal of Clinical Oncology. e15019-e15019. 2011
- Cost-effectiveness of a survivorship care plan for breast cancer survivors.. Journal of Clinical Oncology. 6082-6082. 2011
- Do high symptom scores trigger clinical actions by providers? Assessing the effect of standardized symptom screening.. Journal of Clinical Oncology. 9127-9127. 2011
- Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 4582-4582. 2011
- Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs).. Journal of Clinical Oncology. 2562-2562. 2011
- Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).. Journal of Clinical Oncology. 2011
- Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results.. Journal of Clinical Oncology. 512-512. 2011
- Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.. Journal of Clinical Oncology. 4530-4530. 2011
- Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 185-185. 2011
- Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.. Journal of Clinical Oncology. 118-118. 2011
- Blocking Integrin Function Combined with Ionizing Radiation for Eradication of Bone Metastasis. International Journal of Radiation Oncology Biology Physics. S622-S623. 2010
- HIGH INCONSISTENCIES AMONG LISTS OF CAUTIONED and PROHIBITED DRUGS IN ONCOLOGY PHASE 1 AND PHASE 2 TRIALS. Annals of Oncology. 168-168. 2010
- Accuracy of computerized tomography (CT) imaging in predicting pathologic stage for patients undergoing surgery for transitional cell carcinoma (TCC) of the bladder.. Journal of Clinical Oncology. e15111-e15111. 2010
- Adequacy of data provision and analysis in oncology phase III trials over the past 5 years.. Journal of Clinical Oncology. 6122-6122. 2010
- Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care.. Journal of Clinical Oncology. 9090-9090. 2010
- Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.. Journal of Clinical Oncology. 6031-6031. 2010
- Early stopping rules employing early progression and response compared with conventional stopping rules in actual phase II trials.. Journal of Clinical Oncology. e13004-e13004. 2010
- Inconsistencies among lists of cautioned/prohibited drugs in oncology phase I and phase II trials.. Journal of Clinical Oncology. e13084-e13084. 2010
- Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study.. Journal of Clinical Oncology. 4686-4686. 2010
- Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial.. Journal of Clinical Oncology. 4637-4637. 2010
- CISPLATIN DOSE INTENSITY CORRELATES WITH OUTCOME IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA RECEIVING CONCURRENT CISPLATIN BASED CHEMORADIATION: A MULTI-INSTITUTIONAL EXPERIENCE. Annals of Oncology. 2009
- 8506 Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multi-institutional experience. European Journal of Cancer, Supplement. 472-472. 2009
- Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies. Journal of Clinical Oncology. 2009
- Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer. Journal of Clinical Oncology. e17559-e17559. 2009
- Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer. Journal of Clinical Oncology. 2009
- Trends in the application of dynamic allocation methods in multiarm cancer clinical trials. Journal of Clinical Oncology. 2009
- 382 POSTER Comparison of phase I trial (P1T) abstract quality between the EORTC-NCI-AACR and ASCO meetings. European Journal of Cancer, Supplement. 120-120. 2008
- DELIVERY OF LESS THAN INTENDED CISPLATIN (COOP) DOSE INTENSITY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA-HNSCC) RECEIVING CONCURRENT CHEMORADIATION (CRT) CORRELATES WITH POORER OUTCOME. Radiotherapy and Oncology. S13-S13. 2008
- Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs. 257-264. 2008
- A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 7550-7550. 2008
- A phase II prospective study of standardized steroid dosing for patients with brain metastases undergoing whole brain radiotherapy. Journal of Clinical Oncology. 2050-2050. 2008
- Correlation of deviation from intended cisplatin (CDDP) dose intensity with outcome in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) receiving concurrent chemoradiation (CRT). Journal of Clinical Oncology. 6052-6052. 2008
- Expanded phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 11096-11096. 2008
- Influence of independent review committees (IRC) on assessment of response rate and progression free survival in phase III clinical trials. Journal of Clinical Oncology. 6567-6567. 2008
- The quality of informed consent forms for oncology clinical trials. Journal of Clinical Oncology. 6544-6544. 2008
- Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Annals of Oncology. 481-486. 2008
- NON-RISK ADAPTED SURVEILLANCE IN STAGE I NONSEMINOMATOUS GERM CELL TUMOURS (NSGCT): IMPROVED RECENT OUTCOMES. European Urology Open Science. 85-85. 2008
- Fluororescence in situ hybridization (FISH) gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors (MSGT) treated with lapatinib. Molecular Cancer Therapeutics. 3539S-3539S. 2007
- Association of Rectal Dosimetry and Toxicity With Body Mass Index After Permanent Brachytherapy for Low Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. S329-S329. 2007
- Concurrent Pemetrexed/Cisplatin/Radiation for Unresectable Stage IIIA/B Non-Small Cell Lung Cancer: A Phase I/II Study. International Journal of Radiation Oncology Biology Physics. S490-S490. 2007
- A phase I study of concurrent pemetrexed Cisplatin radiation for unresectable stage IIIA/B non-small cell lung cancer. Radiotherapy and Oncology. S35-S35. 2007
- Can we standardize steroid dose in patients with brain metastases? A prospective study. Radiotherapy and Oncology. S48-S48. 2007
- Is body mass index a predictor for rectal dosimetry and toxicity in 125I permanent implant for low-risk prostate cancer?. Radiotherapy and Oncology. S73-S73. 2007
- Long term urinary sequelae following iodine 125 prostate brachytherapy. Radiotherapy and Oncology. S16-S16. 2007
- The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Radiotherapy and Oncology. S6-S7. 2007
- 6550 POSTER A phase I study of concurrent pemetrexed/cisplatin/radiation for unresectable stage IIIA/B non-small cell lung cancer. European Journal of Cancer, Supplement. 373-373. 2007
- Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma. Journal of Clinical Oncology. 3766-3773. 2007
- PD3-2-5: Preoperative gefitinib in clinical stage I NSCLC. Journal of Thoracic Oncology. S464-S464. 2007
- PD6-1-7: A phase II study of UCN-01 in combination with topotecan in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a study of the Princess Margaret Hospital phase II consortium (PMH-C).. Journal of Thoracic Oncology. S427-S427. 2007
- A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 2007
- A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens. Journal of Clinical Oncology. 2007
- A single agent, phase I pharmacodynamic study of nimotuzumab (TheraClM-h-R3) in patients with advanced refractory solid tumors. Journal of Clinical Oncology. 2007
- Adherence to surveillance guidelines following curative resection for stage II and III colorectal cancer. Journal of Clinical Oncology. 2007
- CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-A trial of the PMH Phase II Consortium. Journal of Clinical Oncology. 2007
- Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC). Journal of Clinical Oncology. 2007
- Correlation between changes in 2-or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966-2006. Journal of Clinical Oncology. 2007
- Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). Journal of Clinical Oncology. 2007
- Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs). Journal of Clinical Oncology. 2007
- Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium. Journal of Clinical Oncology. 2007
- Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium. Journal of Clinical Oncology. 5093-5093. 2007
- The quality of phase I trial (P1T) abstracts submitted to ASCO meetings. Journal of Clinical Oncology. 2007
- W Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study. Journal of Clinical Oncology. 2007
- Evaluation of Cognitive Function Associated With Chemotherapy: A Review of Published Studies and Recommendations for Future Research. Journal of Clinical Oncology. 2455-2463. 2007
- Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology. 2178-2183. 2007
- Pharmacist Medication Assessments in a Surgical Preadmission Clinic. JAMA Internal Medicine. 1034-1034. 2007
- Fractionated stereotactic radiotherapy for acoustic neuroma. Cancer. 1203-1210. 2007
- Predictors of Blood Transfusion Requirements in Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma.. Blood. 2990-2990. 2006
- 2160. International Journal of Radiation Oncology Biology Physics. S299-S300. 2006
- 2413. International Journal of Radiation Oncology Biology Physics. S439-S440. 2006
- 47 POSTER A phase II study of Sorafenib (BAY 43-9006) in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal cancer (NPC): final results. European Journal of Cancer, Supplement. 18-18. 2006
- 550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors. European Journal of Cancer, Supplement. 167-167. 2006
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer. 1148-1154. 2006
- Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents. Journal of Clinical Oncology. 4801-4807. 2006
- The impact of cognitive dysfunction upon the non-metastatic colorectal cancer patient's psychosocial adjustment and quality of life. Psycho-Oncology. S242-S243. 2006
- 162 Radiation dose to the internal pudendal arteries from iodine 125 prostate brachytherapy. Radiotherapy and Oncology. S47-S47. 2006
- 63 Primary and adjuvant chemoradiotherapy for locally advanced pancreatic cancer: A phase I/II study with long term outcome. Radiotherapy and Oncology. S19-S19. 2006
- 69 The impact of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) on radiotherapy planning in carcinoma of the esophagus. Radiotherapy and Oncology. S21-S21. 2006
- A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 13015-13015. 2006
- A randomized controlled trial to evaluate the impact of an educational DVD an cancer patients considering participation in a phase I clinical trial.. Journal of Clinical Oncology. 303S-303S. 2006
- Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study.. Journal of Clinical Oncology. 221S-221S. 2006
- Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study.. Journal of Clinical Oncology. 468S-468S. 2006
- Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function.. Journal of Clinical Oncology. 176S-176S. 2006
- Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer.. Journal of Clinical Oncology. 203S-203S. 2006
- Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital.. Journal of Clinical Oncology. 201S-201S. 2006
- Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial. Journal of Clinical Oncology. 2773-2778. 2006
- Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial.. Journal of Clinical Oncology. 276S-276S. 2006
- Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study.. Journal of Clinical Oncology. 230S-230S. 2006
- A phase II study of ispinesib in patients (PTS) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC). Annals of Oncology. 186-186. 2006
- Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study.. Breast Cancer Research and Treatment. S237-S238. 2006
- Correlation between 2 or 3 year (y) disease-free survival (DFS) and 5y overall survival (OS) in adjuvant systemic trials of early stage breast cancer.. Breast Cancer Research and Treatment. S106-S106. 2006
- Mechanisms of cognitive function and fatigue: A prospective, longitudinal cohort study in colorectal cancer patients. Annals of Oncology. 280-280. 2006
- Phase I clinical trials referrals and enrollment: Five-year experience at the Princess Margaret Hospital. Annals of Oncology. 191-191. 2006
- A phase 2 study of GTI-2040 plus docetaxel and prednisone as 1st line treatment in hormone-refractory prostate cancer (HRPC).. Clinical Cancer Research. 8974S-8974S. 2005
- Correlation between erlotinib concentrations and severity of skin rash.. Clinical Cancer Research. 8993S-8993S. 2005
- Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.. Clinical Cancer Research. 9094S-9094S. 2005
- Pharmacodynamic evaluations of paired tumor biopsies in advanced neuroendocrine carcinomas (NECs) treated with the mTOR inhibitor temsirolimus.. Clinical Cancer Research. 9131S-9131S. 2005
- Pharmacodynamic studies of erlotinib in tumor and skin tissue samples of patients (Pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).. Clinical Cancer Research. 9071S-9071S. 2005
- Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the PMH phase II consortium.. Clinical Cancer Research. 9059S-9059S. 2005
- A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). European Journal of Cancer, Supplement. 297-297. 2005
- A Prospective Study to Evaluate the Need for an Immobilization Device for Treating Modified Mantle Fields in Lymphoma Patients. International Journal of Radiation Oncology Biology Physics. S424-S424. 2005
- Analysis of Gross Target Volume (GTV) Observer Variability with FDG-PET and Contrast Enhanced CT in Head and Neck Cancer Using Finite Element Modeling. International Journal of Radiation Oncology Biology Physics. S363-S364. 2005
- Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens. Journal of Clinical Oncology. 6982-6991. 2005
- Development of fractionated stereotactic radiotherapy for meningioma. European Journal of Cancer, Supplement. 137-137. 2005
- Phase II study of Sorafenib (BAY 43-9006) in combination with Gemcitabine in recurrent epithelial ovarian cancer - a study of the PMH phase II consortium. European Journal of Cancer, Supplement. 272-272. 2005
- Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. European Journal of Cancer, Supplement. 366-366. 2005
- The Relationship of International Prostate Symptom Score with Urinary Flow Studies, and Catheterization Rates Following Iodine 125 Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics. S312-S312. 2005
- The influence of mentorship on research productivity in oncology. European Journal of Cancer, Supplement. 147-147. 2005
- 202 Relationship of the International Prostate Symptom Score with urinary flow studies, and catherization rates following iodine 125 prostate brachytherapy. Radiotherapy and Oncology. S59-S60. 2005
- 58 Radiation target volume delineation (TVD) using FDG-PET and contrast enhanced CT (CECT) for patients with head and neck cancer. Radiotherapy and Oncology. S18-S18. 2005
- 73 A prospective study to evaluate the need for an immobilization device for treating modified mantle fields in lymphoma patients. Radiotherapy and Oncology. S22-S22. 2005
- 95 Stereotactic program development in the management of meningioma. Radiotherapy and Oncology. S29-S29. 2005
- Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. International Journal of Gynecological Cancer. 799-806. 2005
- Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC). Lung Cancer. S256-S256. 2005
- A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC).. Journal of Clinical Oncology. 516S-516S. 2005
- A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs).. Journal of Clinical Oncology. 215S-215S. 2005
- Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors.. Journal of Clinical Oncology. 683S-683S. 2005
- Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the princess margaret hospital [PMH] phase II consortium.. Journal of Clinical Oncology. 422S-422S. 2005
- Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib.. Journal of Clinical Oncology. 865S-865S. 2005
- The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents.. Journal of Clinical Oncology. 529S-529S. 2005
- Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual.. Journal of Clinical Oncology. 789S-789S. 2005
- Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. Journal of Clinical Oncology. 2332-2338. 2005
- Preemptive therapy with ganciclovir and short-course intravenous immunoglobulin does not prevent recurrent cytomegalovirus infection (CBMTG-102 study). Transplantation and Cellular Therapy. 91-91. 2005
- The impact of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of anticancer agents, as perceived by patients, physicians and institution review board members (IRBs). Annals of Oncology. 300-301. 2005
- Weekly cyclophosphamide and alternate day prednisone: An effective, convenient and well tolerated treatment for relapsed multiple myeloma following autologous stem cell transplant.. Blood. 311B-311B. 2004
- Computerized tomographic simulation compared to clinical mark-up in palliative radiotherapy: A prospective study. Radiotherapy and Oncology. S4-S5. 2004
- Penile brachytherapy: Results for 49 patients. Radiotherapy and Oncology. S18-S18. 2004
- Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Does dose escalation improve local recurrence free survival and disease free survival?. Radiotherapy and Oncology. S50-S50. 2004
- Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathological complete response, local recurrence free survival &disease free survival. International Journal of Radiation Oncology Biology Physics. S293-S294. 2004
- Sequential evaluation of prostate edema following permanent seed prostate brachytherapy using CT-MRI fusion. International Journal of Radiation Oncology Biology Physics. S456-S456. 2004
- The use and toxicity of steroids in the management of patients with brain metastases.. Radiotherapy and Oncology. S34-S34. 2004
- Which radiation regimen should be used for Bowen's disease of the skin?. Radiotherapy and Oncology. S36-S36. 2004
- Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens.. Journal of Clinical Oncology. 519S-519S. 2004
- Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada. Journal of Clinical Oncology. 770S-770S. 2004
- Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status.. Journal of Clinical Oncology. 506S-506S. 2004
- Brachytherapy for penile cancer: results for 49 patients. Radiotherapy and Oncology. S61-S62. 2004
- Radiation therapy for Bowen's disease of the skin. International Journal of Radiation Oncology Biology Physics. S574-S575. 2004
- Are Older Cancer Patients Being Referred to Oncologists? A Mail Questionnaire of Ontario Primary Care Practitioners to Evaluate Their Referral Patterns. Journal of Clinical Oncology. 4627-4635. 2003
- A phase I/Il Study of erlotinib (Tarceva) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (HNSCC).. Clinical Cancer Research. 6091S-6091S. 2003
- A phase I/Il Study of erlotinib (Tarceva) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (HNSCC).. Clinical Cancer Research. 6091S-6091S. 2003
- Phase II study of OSI-774 in patients with metastatic colorectal cancer. European Journal of Cancer. S57-S57. 2002
- Geriatric assessment and frailty changes in older patients with Newly-Diagnosed Multiple Myeloma.
- Quality of life assessment in older patients with Newly Diagnosed Multiple Myeloma.
- Trajectory of symptoms after autologous stem cell transplant among patients with Multiple Myeloma: A Population-Based Study
journal articles
- A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer. Breast Cancer Research and Treatment. 208:523-533. 2024
- Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy.. Radiation Oncology. 19:155. 2024
- Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study.. Blood Cancer Journal. 14:181. 2024
- EP.08B.03 Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.. Journal of Thoracic Oncology. 19:s566. 2024
- Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer. 22:102143-102143. 2024
- Safety of vaginal surgery for early-stage cervical cancer: A retrospective multicenter cohort study. European Journal of Surgical Oncology. 50:108518-108518. 2024
- Biopsychosocial Associates of Psychological Distress and Post-Traumatic Growth among Canadian Cancer Patients during the COVID-19 Pandemic.. Current Oncology. 31:5354-5366. 2024
- VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer.. European Urology. S0302-2838(24)02559-4. 2024
- 124 Phase II Randomized Trial of Optimal Recurrence-Directed Therapy (RDT) Without or with Androgen-Deprivation Therapy (ADT) in Radio-Recurrent Oligo-Metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC): The OCOG-Rational-PCS Trial. Radiotherapy and Oncology. 198:s54-s55. 2024
- Development and application of a weighted change score to evaluate interventions for vasomotor symptoms in patients with breast cancer using regression trees: a cohort study. Breast Cancer Research and Treatment. 207:313-321. 2024
- LBA37 Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Annals of Oncology. 35:s1228. 2024
- P-318 A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 24:s217-s218. 2024
- Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study.. Hematology Journal. 2024
- Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy. BMC Cancer. 24:984. 2024
- A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer. Current Oncology. 31:4531-4545. 2024
- Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey. Breast Cancer Research and Treatment. 206:473-481. 2024
- HPV Self-Sampling for Cervical Cancer Screening in Under-Screened Saskatchewan Populations: A Pilot Study. Current Oncology. 31:4261-4269. 2024
- Patterns of Survivorship Follow-Up Care Among Patients With Breast Cancer: A Retrospective Population-Based Cohort Study in Ontario, Canada, Between 2006 and 2016. JCO Oncology Practice. OP2300813. 2024
- Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL). Leukemia and Lymphoma. 65:1167-1174. 2024
- ASO Visual Abstract: Immigration Status and Breast Cancer Surgery Quality of Care Metrics: A Population-Level Analysis. Annals of Surgical Oncology. 31:4549-4550. 2024
- Comparison of Multiparametric MRI–targeted and Systematic Biopsies for Detection of Cribriform and Intraductal Carcinoma Prostate Cancer. Radiology. 312:e231948. 2024
- Immigration Status and Breast Cancer Surgery Quality of Care Metrics: A Population-Level Analysis. Annals of Surgical Oncology. 31:4518-4526. 2024
- Stereotactic Ablative Radiotherapy for Gynecological Oligometastatic and Oligoprogessive Tumors. JAMA Oncology. 10:941-941. 2024
- Patient and Provider Attitudes and Preferences Regarding Early Palliative Care Delivery for Patients with Advanced Gastrointestinal Cancers: A Prospective Survey. Current Oncology. 31:3329-3341. 2024
- Oncologists’ Satisfaction with Virtual Care: A Questionnaire. Current Oncology. 31:3269-3277. 2024
- Incidence of venous thromboembolism in newly diagnosed glioblastoma multiforme and associated risk factors: A retrospective chart review.. Journal of Clinical Oncology. 42:e14040-e14040. 2024
- Magnetic Resonance Imaging–Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE). European urology oncology. 7:456-461. 2024
- Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clinical Lymphoma, Myeloma and Leukemia. 24:e227-e234. 2024
- Abstract PO3-11-12: A Pragmatic Randomized Trial Comparing Morning versus Evening Dosing of Endocrine Therapy for Early Breast Cancer: Final Results (REaCT-CHRONO Study). Cancer Research. 84:po3-11-12-po3-11-12. 2024
- Abstract PO4-13-01: A randomised trial comparing 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early breast cancer (REaCT-ZOL): Quality of life and toxicity outcomes. Cancer Research. 84. 2024
- Abstract PO5-01-11: Breast Cancer Index and comparative analysis of late distant recurrence risk with results from the TEAM trial. Cancer Research. 84:po5-01-11-po5-01-11. 2024
- Abstract PS16-03: Intratumoral dosing of INT230-6 in Early-Stage Breast Cancer Patients Induces Tumor Cell Necrosis and Immunomodulatory Effects: A Phase II Randomized Window-Of-Opportunity Study – the INVINCIBLE Trial. Cancer Research. 84:ps16-03-ps16-03. 2024
- 126P A randomized controlled trial (RCT) comparing optimal local treatment with or without endocrine therapy (ET) in patients (pts) aged ≥70 with lower risk breast cancer (BC) [REaCT-70 Study]. ESMO Open. 9:103114-103114. 2024
- Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial. Clinical Cancer Research. 30:1509-1517. 2024
- A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial. Journal of Geriatric Oncology. 15:101735-101735. 2024
- Acute Toxicity Results from the Randomized Assessment of Cisplatin Dosing Interval for Ototoxicity (RADIO) Trial Comparing Chemoradiation (CRT) with Cisplatin Q3weekly to Weekly for Locally Advanced Squamous Cell Carcinoma of the Head and neck (LASCCHN). International Journal of Radiation Oncology Biology Physics. 118:e9-e9. 2024
- Gender and Racial Diversity Among Obstetrics and Gynecology Departments and Gynecologic Oncology Divisions in Canada: Are We There Yet?. Journal of Obstetrics and Gynaecology Canada. 46:102350-102350. 2024
- The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey. Breast Cancer Research and Treatment. 204:531-538. 2024
- Abstract 4798: MRI screening for brain metastases (BrM) versus SYMptom-directed brain imaging for patients with triple negative (TN) or HER2+ metastatic breast cancer (MBC): An ad-hoc interim analysis of a randomized phase II pilot study. Cancer Research. 84:4798-4798. 2024
- Enhancing Nutrition Support for Esophageal Cancer Patients: Understanding Factors Influencing Feeding Tube Utilization. Nutrition and Cancer. 76:271-278. 2024
- The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care. Current Oncology. 31:1376-1388. 2024
- Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study. Current Oncology. 31:1278-1290. 2024
- Evaluating equity of access and predictors of minimally invasive hysterectomy for endometrial and cervical cancer from 2000 to 2017 in Ontario, Canada: A population‐based cohort study. Journal of Surgical Oncology. 129:392-402. 2024
- Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use. Current Oncology. 31:425-435. 2024
- Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending. BMJ Oncology. 3:e000287-e000287. 2024
- Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Current Oncology. 30:10477-10487. 2023
- Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. Journal of the National Cancer Institute. 115:1605-1615. 2023
- A randomised controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairment. Journal of Cancer Survivorship. 17:1583-1595. 2023
- Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Hematology Journal. 108:3384-3391. 2023
- Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance. International Journal of Molecular Sciences. 24:16022-16022. 2023
- Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant. Blood. 142:2211-2211. 2023
- Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study. Blood. 142:541-541. 2023
- Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Blood. 142:3774-3774. 2023
- Rates of surgery and adjuvant chemotherapy use in patients with stage IB to IIIA non-small cell lung cancer: A provincial population-based study.. JCO Oncology Practice. 19:134-134. 2023
- Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysis. Journal of Geriatric Oncology. 14:101592-101592. 2023
- 2361MO Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC) [PET-MUSE]. Annals of Oncology. 34:S1200-S1200. 2023
- Circulating Growth Differentiation Factor 15 as a Biomarker in Patients with Unresected Locally Advanced Non-Small Cell Lung Cancer Treated with Chemo-Radiotherapy with or without Metformin. International Journal of Radiation Oncology Biology Physics. 117:e14-e15. 2023
- Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets. JCO clinical cancer informatics. 7:e2300116. 2023
- Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer. New England Journal of Medicine. 389:612-619. 2023
- Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology—A National Questionnaire. Current Oncology. 30:7627-7637. 2023
- A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer. Current Oncology. 30:7384-7397. 2023
- Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study. American Journal of Hematology. 98:E197-E199. 2023
- Can routinely collected administrative data effectively be used to evaluate and validate endpoints used in breast cancer clinical trials? Protocol for a scoping review of the literature. Systematic Reviews. 12:117. 2023
- BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer Treated With External Beam Radiation With or Without High-Dose-Rate Intraluminal Brachytherapy. International Journal of Radiation Oncology Biology Physics. 116:601-610. 2023
- Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study. Gynecologic Oncology. 174:21-27. 2023
- Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial.. Journal of Clinical Oncology. 41:509-509. 2023
- Can synthetic data accurately mimic oncology clinical trials?. Journal of Clinical Oncology. 41:1554-1554. 2023
- Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.. Journal of Clinical Oncology. 41:533-533. 2023
- Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach.. Journal of Clinical Oncology. 41:e24126-e24126. 2023
- Multisystem immune-related adverse events from dual agent immunotherapy use.. Journal of Clinical Oncology. 41:2635-2635. 2023
- P-418 Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study. Annals of Oncology. 34:S159-S159. 2023
- Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.. Journal of Clinical Oncology. 41:573-573. 2023
- Regularly scheduled physical examinations and the detection of breast cancer recurrences. Breast. 69:274-280. 2023
- Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study.. Journal of Clinical Oncology. 41:e18694-e18694. 2023
- Differentiating Specialized and Advanced Nursing Roles: The Pathway to Role Optimization. Nursing Leadership. 36:57-74. 2023
- P021 A pragmatic randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy for early breast cancer (REaCT-CHRONO Study). Breast. 68:S24-S25. 2023
- P279 A patient survey evaluating COVID-19-induced changes in follow-up of patients with EBC: opportunities for enhanced evidence-based practice?. Breast. 68:S127-S127. 2023
- P291 Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers. Breast. 68:S132-S132. 2023
- Rurality index score and pediatric neuro-oncological outcome in Ontario. Journal of Neurosurgery: Pediatrics. 31:275-281. 2023
- Abstract P2-02-04: De-escalation of bone-targeted treatment: Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Cancer Research. 83. 2023
- Abstract P2-11-10: Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial. Cancer Research. 83. 2023
- Abstract P2-13-04: Inclusion of Patients with Leptomeningeal Disease in Phase III Randomized Clinical Trials of Patients with Advanced Breast Cancer, Lung Cancer, and Melanoma: A Systematic Review. Cancer Research. 83. 2023
- Abstract P5-04-04: Does reducing the frequency of regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?. Cancer Research. 83. 2023
- Abstract P6-05-12: Understanding Patient Perspectives on Window of Opportunity Clinical Trial Participation in Breast Cancer. Cancer Research. 83. 2023
- Abstract PD11-02: PD11-02 A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 in Early Stage Breast Cancer: the INVINCIBLE Trial. Cancer Research. 83. 2023
- Developing a Data and Analytics Platform to Enable a Breast Cancer Learning Health System at a Regional Cancer Center. JCO clinical cancer informatics. 7:e2200182. 2023
- Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities. Journal of the National Comprehensive Cancer Network : JNCCN. 21:247-256.e8. 2023
- FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.. Journal of Clinical Oncology. 41:460-460. 2023
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. 41:TPS750-TPS750. 2023
- Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).. Journal of Clinical Oncology. 41:5-5. 2023
- Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study. Current Oncology. 30:1977-1985. 2023
- Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study. Clinical Oncology. 35:e182-e188. 2023
- Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer. Journal of Thoracic Disease. 15:423-433. 2023
- Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. European Journal of Cancer. 180:108-116. 2023
- Web-Based Asynchronous Tool to Facilitate Communication Between Primary Care Providers and Cancer Specialists: Pragmatic Randomized Controlled Trial. Journal of Medical Internet Research. 25:e40725-e40725. 2023
- Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer. Cancers. 15:571-571. 2023
- Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma. Neuro-Oncology Practice. 10:89-96. 2023
- Increasing palliative care capacity in primary care: study protocol of a cluster randomized controlled trial of the CAPACITI training program. BMC Palliative Care. 22:2. 2023
- Assessing Access to And Outcomes of Medical Oncology and Radiation Oncology Consultation in Non-Small Cell Lung Cancer Patients: A Population-Based Study Using Administrative Data. Medical Research Archives. 11. 2023
- The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada. Frontiers in Oncology. 13:1210945. 2023
- Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study. Gynecologic Oncology. 167:532-539. 2022
- Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis. Current Oncology. 29:9046-9065. 2022
- Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas. Blood. 140:8036-8037. 2022
- Radiation Dose, Technique and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics. 114:e411-e411. 2022
- Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer. Clinical Breast Cancer. 22:629-633. 2022
- Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.. Journal of Clinical Oncology. 40:332-332. 2022
- 116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis. Annals of Oncology. 33:S591-S592. 2022
- 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial. Annals of Oncology. 33:S602-S602. 2022
- 139: Radiotherapy Dose, FDG-PET Utilization and Survival Outcomes of Unresected Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). Ontario Population Outcomes of Contemporary Radiotherapy Alone and Standard of Care Chemo-Radiotherapy. Radiotherapy and Oncology. 174:S59-S60. 2022
- 179: The Evolution of Technology in the Management of Early-Stage (T1) Cancer of the Larynx, an Institutional Review of Radiation Therapy Outcomes. Radiotherapy and Oncology. 174:S74-S74. 2022
- 68: Radiation Dose, Technique, and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer. Radiotherapy and Oncology. 174:S31-S31. 2022
- 88: Outcomes of Radiotherapy Alone for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) in Patients Unfit for Chemo-Radiotherapy. Radiotherapy and Oncology. 174:S39-S39. 2022
- P1.15-10 Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada. Journal of Thoracic Oncology. 17:S124-S124. 2022
- Using machine learning to predict individual patient toxicities from cancer treatments. Supportive Care in Cancer. 30:7397-7406. 2022
- Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial. Journal of Experimental and Clinical Cancer Research. 41:255. 2022
- Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study. Gynecologic Oncology. 166:230-235. 2022
- Germline BRCA mutations are associated with an increased likelihood of secondary cytoreductive surgery in ovarian cancer patients (116). Gynecologic Oncology. 166:S75-S76. 2022
- The status of surgical margins in relation to the type of surgical approach in the management of early-stage cervical cancer: Canadian Cervical Cancer Collaborative (4C) study (533). Gynecologic Oncology. 166:S261-S261. 2022
- Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer. Journal of Molecular Diagnostics. 24:775-783. 2022
- Lack of cognitive impairment in long-term survivors of colorectal cancer. Supportive Care in Cancer. 30:6123-6133. 2022
- LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T₁N₀ luminal A breast cancer (BC).. Journal of Clinical Oncology. 40:LBA501-LBA501. 2022
- Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer. Cancer Epidemiology, Biomarkers and Prevention. 33:831-841. 2022
- Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.. Journal of Clinical Oncology. 40:e18628-e18628. 2022
- Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).. Journal of Clinical Oncology. 40:605-605. 2022
- Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.. Journal of Clinical Oncology. 40:e21172-e21172. 2022
- SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.. Journal of Clinical Oncology. 40:9573-9573. 2022
- Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?. Journal of Clinical Oncology. 40:1532-1532. 2022
- Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead. JAMA Oncology. 8:679-679. 2022
- Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. Supportive Care in Cancer. 30:3977-3984. 2022
- The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers. Gynecologic Oncology. 165:317-322. 2022
- Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. BMJ Open. 12:e055735-e055735. 2022
- Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience. Supportive Care in Cancer. 30:4437-4446. 2022
- Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial). Cancer Research. 82. 2022
- Abstract OT1-06-01: A randomised trial comparing continuation or de-escalation of bone modifying agents (BMA) in patients treated for over 2 years for bone metastases from either breast or castration-resistant prostate cancer (REaCT-HOLD BMA). Cancer Research. 82. 2022
- Abstract OT1-07-01: MRI screening versus symptom-directed surveillance for brain metastases among patients with triple negative or HER2+ metastatic breast cancer: A pilot study (nct03881605). Cancer Research. 82. 2022
- Abstract OT1-11-02: A pragmatic, randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy and its effects on tolerability and compliance (REaCT-CHRONO Study). Cancer Research. 82. 2022
- Incidence and Predictors of Prosthetic Joint Infection Following Primary Total Knee Arthroplasty: A 15-Year Population-Based Cohort Study. Journal of Arthroplasty. 37:367-372.e1. 2022
- Metformin—A Thought-provoking Addition to Anticancer Therapies—Reply. JAMA Oncology. 8:303-303. 2022
- Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study. Blood Cancer Journal. 12:17. 2022
- A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer. PLoS ONE. 17:e0263345-e0263345. 2022
- Abstract PO-142: Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer. Cancer Epidemiology, Biomarkers and Prevention. 31. 2022
- A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. Current Oncology. 28:5073-5083. 2021
- A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer. BMC Cancer. 21:14. 2021
- Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer. 19:540-546. 2021
- Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration. BJU International. 128:607-614. 2021
- Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. Supportive Care in Cancer. 29:6903-6912. 2021
- 100: The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario between 2009-2017. Radiotherapy and Oncology. 163:S44-S44. 2021
- Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. Clinical Genitourinary Cancer. 19:425-433. 2021
- Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study. Breast Cancer Research and Treatment. 189:797-806. 2021
- Response to ‘Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors’. Heart. 107:1680.2-1681. 2021
- Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. Journal of Bone Oncology. 30:100388-100388. 2021
- Hypofractionated Stereotactic Radiotherapy for the Treatment of Benign Intracranial Meningiomas: Long-Term Safety and Efficacy. Current Oncology. 28:3683-3691. 2021
- Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology. 7:1333-1333. 2021
- Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. Clinical Lymphoma, Myeloma and Leukemia. 21:e714-e721. 2021
- A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Breast. 58:42-49. 2021
- Risk Perception Among a Lung Cancer Screening Population. Chest. 160:718-730. 2021
- Advancing Academic Cancer Clinical Trials Recruitment in Canada. Current Oncology. 28:2830-2839. 2021
- Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse. Current Oncology. 28:2778-2788. 2021
- Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study. npj Breast Cancer. 7:90. 2021
- Central Nervous System–Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma. JAMA Oncology. 7:1062-1062. 2021
- Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers. Breast Cancer Research and Treatment. 188:343-350. 2021
- Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study. Hematology Journal. 106:1991-1994. 2021
- Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection. Current Oncology. 28:2399-2408. 2021
- A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy. Supportive Care in Cancer. 29:3113-3120. 2021
- Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey. Breast Cancer Research and Treatment. 187:477-486. 2021
- EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO. Neuro-Oncology. 23:i49-i49. 2021
- EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO. Neuro-Oncology. 23:i49-i49. 2021
- External validation of the FIRST trial’s simplified frailty score in a population-based cohort. Leukemia. 35:1823-1827. 2021
- Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. Current Oncology. 28:1847-1856. 2021
- Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. Journal of Geriatric Oncology. 12:508-514. 2021
- The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?. Gynecologic Oncology. 161:361-366. 2021
- Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. Journal of Bone Oncology. 27:100351-100351. 2021
- Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. JAMA Oncology. 7:534-534. 2021
- Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease. Heart. 107:667-673. 2021
- Abstract PS14-18: A physician survey evaluating real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast cancer. Cancer Research. 81:ps14-18-ps14-18. 2021
- Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. Journal of Bone Oncology. 26:100343-100343. 2021
- Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey. Journal of Bone Oncology. 26:100339-100339. 2021
- A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. European Journal of Cancer. 142:132-140. 2021
- Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system. PLoS ONE. 16:e0251886-e0251886. 2021
- Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology. 6:100553-100553. 2021
- A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction. Current Oncology. 28:184-195. 2020
- Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. BMC Pulmonary Medicine. 20:300. 2020
- Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. Investigative Urology. 204:1173-1179. 2020
- Assessment of spring water quality in Jhimruk River Watershed, Lesser Himalaya, Nepal. Environmental Earth Sciences. 79. 2020
- Disparities in surgical management of endometrial cancers in a public healthcare system: A question of equity. Gynecologic Oncology. 159:387-393. 2020
- Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. Journal of Geriatric Oncology. 11:1279-1284. 2020
- Investigating the appropriateness of different concordance measures in a time‐to‐event setting. Pharmaceutical Statistics. 19:763-775. 2020
- Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European urology oncology. 3:695-699. 2020
- Oncologists and Medical Assistance in Dying: Where Do We Stand? Results of a National Survey of Canadian Oncologists. Current Oncology. 27:263-269. 2020
- Oncologists and Medical Assistance in Dying: Where Do We Stand? Results of a National Survey of Canadian Oncologists.. Current Oncology. 27:263-269. 2020
- 212: Cardiac Morbidity Following Radical Thoracic Chemoradiotherapy for Locally Advanced Lung Cancer: A Population-Based Cohort Study. Radiotherapy and Oncology. 150:S90-S90. 2020
- 77: Dosimetric Comparison of Conformal Radiation Therapy (Crt), Imrt and Vmat for Esophageal Cancer Treated with External Radiation. Radiotherapy and Oncology. 150:S35-S36. 2020
- Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. European urology oncology. 3:540-543. 2020
- A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Annals of Oncology. 31:951-957. 2020
- Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study. Gynecologic Oncology. 158:130-136. 2020
- Erratum to: Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. Int J Radiat Oncol Biol Phys 2020;106:546-555.. International Journal of Radiation Oncology Biology Physics. 107:390-390. 2020
- A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.. Journal of Clinical Oncology. 38:7001-7001. 2020
- Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.. Journal of Clinical Oncology. 38:5043-5043. 2020
- Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 38:e17044-e17044. 2020
- Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.. Journal of Clinical Oncology. 38:5048-5048. 2020
- High triple‐negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer. Cancer. 126:2217-2224. 2020
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Journal of the Canadian Urological Association. 14:123-130. 2020
- Routine Imaging or No Routine Imaging, Is That the Question?. Journal of the National Comprehensive Cancer Network : JNCCN. 18:490-492. 2020
- Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study. Clinical Trials. 17:202-211. 2020
- Risk Factors for Periprosthetic Joint Infection Following Primary Total Hip Arthroplasty. Journal of Bone and Joint Surgery. American volume. 102:503-509. 2020
- A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. International Journal of Radiation Oncology Biology Physics. 106:546-555. 2020
- Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 8:e000371-e000371. 2020
- Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. European Urology. 77:311-317. 2020
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer.. npj Breast Cancer. 6:6. 2020
- A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma.. Journal of Clinical Oncology. 38:692-692. 2020
- Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 38:473-473. 2020
- Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors.. Journal of Clinical Oncology. 38:481-481. 2020
- Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy.. Journal of Clinical Oncology. 38:540-540. 2020
- SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.. Journal of Clinical Oncology. 38:TPS65-TPS65. 2020
- Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information. Clinical Breast Cancer. 20:61-67. 2020
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. npj Breast Cancer. 6:6. 2020
- The impact of synchronous malignancies on survival in patients with early stage curable non-small-cell lung cancer. Cancer Treatment and Research Communications. 25:100246-100246. 2020
- A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases. Cureus. 11:e6394. 2019
- Learning Health System for Breast Cancer: Pilot Project Experience. JCO clinical cancer informatics. 3:1-11. 2019
- Age-Related Survival Differences in Patients With Inflammatory Bowel Disease–Associated Colorectal Cancer: A Population-Based Cohort Study. Inflammatory Bowel Diseases. 25:1957-1965. 2019
- A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. Breast Cancer Research and Treatment. 178:327-335. 2019
- Is Access to Care Associated With Stage at Presentation and Survival for Melanoma Patients?. Medical and Surgical Dermatology. 23:586-594. 2019
- Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients. Breast Cancer Research and Treatment. 178:347-356. 2019
- 105 Cyberknife Stereotactic Radiosurgery for Treatment of Benign Intracranial Meningioma: Long-Term Safety and Efficacy. Radiotherapy and Oncology. 139:S46-S47. 2019
- 122 A Comparison of Radiation Techniques in Patients Treated with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. Radiotherapy and Oncology. 139:S53-S53. 2019
- Changes in Soft-Tissue Sarcoma Treatment Patterns over Time: A Population-Based Study in a Country with Universal and Centralized Healthcare. Sarcoma. 2019:1-7. 2019
- The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸F-Fluoromethylcholine or ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Journal of Nuclear Medicine. 60:1253-1258. 2019
- MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins. Clinical Oncology. 31:479-485. 2019
- Prospective, Multisite, International Comparison of ¹⁸F-Fluoromethylcholine PET/CT, Multiparametric MRI, and ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. Journal of Nuclear Medicine. 60:794-800. 2019
- A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.. Journal of Clinical Oncology. 37:11501-11501. 2019
- Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).. Journal of Clinical Oncology. 37:e16038-e16038. 2019
- A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases. Annals of Oncology. 30:iii73-iii73. 2019
- Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer. Cancer. 125:1459-1469. 2019
- A prospective intervention to improve happiness and reduce burnout in oncologists. Supportive Care in Cancer. 27:1563-1572. 2019
- Methods to improve the estimation of time‐to‐event outcomes when data is de‐identified. Statistics in Medicine. 38:625-635. 2019
- Abstract PD6-04: Lifestyle intervention study (LISA) in early breast cancer (BC): An RCT of the effects of a telephone-based weight loss intervention (with educational materials) vs educational materials alone on disease-free survival (DFS). Cancer Research. 79:pd6-04-pd6-04. 2019
- A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging and Behavior. 13:15-26. 2019
- Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. European Urology. 75:300-309. 2019
- Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer. 17:7-14.e3. 2019
- Early initiation of palliative care is associated with reduced late-life acute-hospital use: A population-based retrospective cohort study. Palliative Medicine. 33:150-159. 2019
- Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute. 111:118-128. 2019
- Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer. American Journal of Clinical Oncology. 42:56-59. 2019
- Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study. European Urology Focus. 4:937-945. 2018
- Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European Urology Focus. 4:874-879. 2018
- RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS. Neuro-Oncology. 20:vi234-vi235. 2018
- RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS. Neuro-Oncology. 20:vi234-vi235. 2018
- Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study. Breast Cancer Research and Treatment. 171:709-717. 2018
- Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer. Cureus. 10:e3387. 2018
- Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer. JAMA network open. 1:e182081-e182081. 2018
- Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort. World Journal of Urology. 36:1423-1429. 2018
- Pretreatment neurocognitive function and self‐reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. Head and Neck. 40:2029-2042. 2018
- Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Supportive Care in Cancer. 26:3073-3081. 2018
- Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clinical Genitourinary Cancer. 16:e961-e967. 2018
- Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab. Breast Cancer Research and Treatment. 170:169-177. 2018
- Uncertain times: A survey of Canadian women's perspectives toward mammography screening. Preventive Medicine. 112:209-215. 2018
- 41 Does exercise improve progression free survival (PFS) and quality of life (QOL) in patients with glioblastoma? A trial in progress. Canadian Journal of Neurological Sciences. 45:S8-S8. 2018
- Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. Cancer Epidemiology, Biomarkers and Prevention. 27:627-635. 2018
- Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 36:4540-4540. 2018
- Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 124:2115-2124. 2018
- Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget. 9:19861-19873. 2018
- Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical Genitourinary Cancer. 16:e483-e490. 2018
- Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. Clinical Genitourinary Cancer. 16:e277-e287. 2018
- Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. Journal of Cancer Survivorship. 12:178-185. 2018
- Quality of preoperative pelvic computed tomography (CT) and magnetic resonance imaging (MRI) for rectal cancer in a region in Ontario: A retrospective population‐based study. Journal of Surgical Oncology. 117:1038-1042. 2018
- Active surveillance magnetic resonance imaging study (ASIST): Results of a prospective, multicentre, randomized trial. European Urology Open Science. 17:e1711-e1712. 2018
- Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer. Journal of Bone Oncology. 10:6-13. 2018
- Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study. European Urology Open Science. 17:e519-e520. 2018
- Abstract P3-08-12: Prognostic relevance of neutrophil-to-lymphocyte ratio (NLR) in young women with breast cancer (BC). Cancer Research. 78:p3-08-12-p3-08-12. 2018
- C-statistic: A brief explanation of its construction, interpretation and limitations. European Journal of Cancer. 90:130-132. 2018
- Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. JAMA Otolaryngology - Head and Neck Surgery. 144:71-79. 2018
- Outcome analysis of visual acuity and side effect after ruthenium-106 plaque brachytherapy for medium-sized choroidal melanoma. Middle East African Journal of Ophthalmology. 25:103-103. 2018
- Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer. ESMO Open. 3:e000302-e000302. 2018
- Validation of a modified VOICES survey to measure end-of-life care quality: the CaregiverVoice survey. BMC Palliative Care. 16:44. 2017
- Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clinical Genitourinary Cancer. 15:635-641. 2017
- Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry. Journal of Medical Genetics. 54:742-746. 2017
- Pattern of relapse after perioperative chemotherapy and radical cystectomy versus radical cystectomy alone in patients with muscle-invasive bladder cancer (MIBC): A multicenter study. European Urology Open Science. 16:e2794-e2795. 2017
- Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clinical Genitourinary Cancer. 15:548-555.e3. 2017
- Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population. Annals of Oncology. 28:v308-v309. 2017
- Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials. Oncotarget. 8:57733-57754. 2017
- Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.. Oncotarget. 8:57733-57754. 2017
- A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). Clinical Lung Cancer. 18:436-440.e1. 2017
- PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Medicine (United States). 96:e6817-e6817. 2017
- A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer. Annals of Oncology. 28:i4-i5. 2017
- A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors. Clinical Genitourinary Cancer. 15:306-312. 2017
- A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors. Clinical Genitourinary Cancer. 15:306-312.e3. 2017
- Comparative Survival in Patients with Brain Metastases from Non-small-Cell Lung Cancer Treated before and after Implementation of Radiosurgery. Current Oncology. 24:146-151. 2017
- Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)‐1 or PD ligand 1 inhibitor therapy. BJU International. 119:579-584. 2017
- Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 20:67-71. 2017
- Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.. Journal of Clinical Oncology. 35:334-334. 2017
- Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.. Journal of Clinical Oncology. 35:149-149. 2017
- Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.. Journal of Clinical Oncology. 35:346-346. 2017
- Abstract P4-12-09: The immune response in triple negative breast cancer. Cancer Research. 77:p4-12-09-p4-12-09. 2017
- A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. Lung Cancer. 104:65-69. 2017
- Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer. 15:23-30.e2. 2017
- Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 15:53-59. 2017
- Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 15:53-59. 2017
- Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer. Journal of Gastrointestinal Oncology. 8:32-38. 2017
- Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. PLoS ONE. 12:e0168669-e0168669. 2017
- Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 14:494-498. 2016
- A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer. Journal of Bone Oncology. 5:173-179. 2016
- Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non–small-Cell Lung Cancer. Clinical Lung Cancer. 17:563-572.e2. 2016
- Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology. 34:3537-3543. 2016
- PS1 -125 Assessment of Function and Quality of Life in a Phase II Multi-Institutional Clinical Trial of Fractionated Simultaneous In-Field Boost Radiotherapy for Patients with 1-2 Brain Metastases. Canadian Journal of Neurological Sciences. 43:S8-S8. 2016
- 140: Indentification of Curculating MIRNA Associated with Development of Castrate Resistance in High-Risk and Biochemically Recurrent Prostate Cancer Patients. Radiotherapy and Oncology. 120:S52-S52. 2016
- 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology. 120:S83-S83. 2016
- Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. Annals of Oncology. 27:1761-1767. 2016
- Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clinical Genitourinary Cancer. 14:331-340. 2016
- Metformin for chemo-radio-sensitization of NSCLC. Radiotherapy and Oncology. 120:363-364. 2016
- Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1–3 metastases. Journal of Neuro-Oncology. 128:431-436. 2016
- Prospective comparison of rectal dose reduction during intracavitary brachytherapy for cervical cancer using three rectal retraction techniques. Brachytherapy. 15:450-455. 2016
- Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. Investigative Urology. 196:95-100. 2016
- Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. European Urology. 69:980-983. 2016
- Can the Referring Surgeon Enhance Accrual of Breast Cancer Patients to Medical and Radiation Oncology Trials? The Enhance Study. Current Oncology. 23:276-279. 2016
- 84P Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside. Journal of Thoracic Oncology. 11:S91-S91. 2016
- A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Investigational New Drugs. 34:231-235. 2016
- Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer — At What Cost? Eur Urol 2016;69:642–44. European Urology. 69:644-645. 2016
- Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. European Urology. 69:634-641. 2016
- Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.. European Urology. 69:634-641. 2016
- The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology. 69:624-633. 2016
- A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 17:142-149. 2016
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. Investigative Urology. 195:277-282. 2016
- Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. Clinical Lymphoma, Myeloma and Leukemia. 16:18-28.e4. 2016
- Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. Frontiers in Pharmacology. 7:487. 2016
- A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship. 9:683-691. 2015
- Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. Journal of Clinical Oncology. 33:4085-4092. 2015
- Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget. 6:35183-35201. 2015
- Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis. Annals of Oncology. 26:vi55-vi55. 2015
- Factors associated with acute care use among nursing home residents dying of cancer: a population-based study. International Journal of Palliative Nursing. 21:349-356. 2015
- Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study. Journal of Bone Oncology. 4:47-53. 2015
- Factors associated with not receiving homecare, end-of-life homecare, or early homecare referral among cancer decedents: A population-based cohort study. Health Policy. 119:831-839. 2015
- Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clinical Genitourinary Cancer. 13:250-256. 2015
- Independent predictors of prolonged operative time during robotic-assisted radical prostatectomy. Journal of Robotic Surgery. 9:117-123. 2015
- Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. BJU International. 115:854-855. 2015
- Time Interval Between Endometrial Biopsy and Surgical Staging for Type I Endometrial Cancer. Obstetrics and Gynecology. 125:1497-1498. 2015
- Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors.. Journal of Clinical Oncology. 33:TPS9636-TPS9636. 2015
- Expression of thyroid hormone receptor alpha (THRα) isoforms in triple negative breast cancer (TNBC).. Journal of Clinical Oncology. 33:e12082-e12082. 2015
- 596 Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration. European Urology Open Science. 14:e596-e596a. 2015
- Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. Clinical Genitourinary Cancer. 13:178-184. 2015
- Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. Clinical Genitourinary Cancer. 13:185-192. 2015
- Influence of censoring on conclusions of trials for women with metastatic breast cancer. European Journal of Cancer. 51:721-724. 2015
- Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy. Oncotarget. 6:7040-7052. 2015
- Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design. Clinical Genitourinary Cancer. 13:71-79. 2015
- A prospective comparison of MRI‐US fused targeted biopsy versus systematic ultrasound‐guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. Journal of Magnetic Resonance Imaging. 41:220-225. 2015
- Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer. International Journal of Surgical Oncology. 2015:1-9. 2015
- Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications. Breast Cancer Research and Treatment. 149:293-301. 2015
- Cognitive function and fatigue after diagnosis of colorectal cancer. Annals of Oncology. 25:2404-2412. 2014
- Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma. Clinical Genitourinary Cancer. 12:440-446. 2014
- Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. SpringerPlus. 3:577. 2014
- Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 12:395-398. 2014
- Radiographic progression by Prostate Cancer Working Group (PCWG)‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer. BJU International. 114:E25-E31. 2014
- Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib. Journal of the Canadian Urological Association. 8:398-398. 2014
- Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer. Annals of Oncology. 25:2096-2096. 2014
- Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 12:317-324. 2014
- Angiogenic Switch As Predictor of Response to Chemotherapy+ Bevacizumab in Patients with Metastatic Colorectal Cancer. Annals of Oncology. 25:iv181-iv181. 2014
- Outcomes with Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma (Uc) Following Previous Perioperative Cisplatin-Based Therapy. Annals of Oncology. 25:iv302-iv302. 2014
- The Significance of Complete Response (Cr) in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma (Uc). Annals of Oncology. 25:iv301-iv301. 2014
- Factors Associated with Publication of Randomized Phase iii Cancer Trials in Journals with a High Impact Factor. Current Oncology. 21:564-572. 2014
- Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. Journal of Clinical Oncology. 32:2231-2239. 2014
- Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods. Clinical Biochemistry. 47:897-900. 2014
- Phase 1 Trial Design: Is 3 + 3 the Best?. Cancer Control. 21:200-208. 2014
- Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Research and Treatment. 146:153-162. 2014
- Reply to J. Menczer. Journal of Clinical Oncology. 32:2114-2114. 2014
- Treatment Delay in Endometrial Cancer. Journal of Clinical Oncology. 32:2113-2114. 2014
- A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma. BJU International. 113:E137-E143. 2014
- Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. Urologic Oncology: Seminars and Original Investigations. 32:501-508. 2014
- Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology. 25:992-998. 2014
- A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Research and Treatment. 144:615-624. 2014
- Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. Journal of Geriatric Oncology. 5:119-126. 2014
- Cost Effectiveness of a Survivorship Care Plan for Breast Cancer Survivors. JCO Oncology Practice. 10:e86-e92. 2014
- Are family physician visits and continuity of care associated with acute care use at end-of-life? A population-based cohort study of homecare cancer patients. Palliative Medicine. 28:176-183. 2014
- Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations. 32:36.e27-36.e34. 2014
- High-Sensitivity Cardiac Troponin I for Predicting Death in a Female Emergency Department Population. Clinical Chemistry. 60:271-273. 2014
- Impact of Wait Times on Survival for Women With Uterine Cancer. Journal of Clinical Oncology. 32:27-33. 2014
- Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urologic Oncology: Seminars and Original Investigations. 32:48.e1-48.e8. 2014
- Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis. Oncology Research and Treatment. 37:772-776. 2014
- The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer. European Urology. 65:3-6. 2014
- Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy. Clinical Genitourinary Cancer. 11:423-430. 2013
- Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design. Clinical Genitourinary Cancer. 11:495-500. 2013
- Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Annals of Oncology. 24:2972-2977. 2013
- Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials. Urologic Oncology: Seminars and Original Investigations. 31:1457-1463. 2013
- The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000–2009. Gynecologic Oncology. 131:151-157. 2013
- Data collection in cancer clinical trials: Too much of a good thing?. Clinical Trials. 10:624-632. 2013
- The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada during 2000-2009. Gynecologic Oncology. 130:e40-e41. 2013
- Potential Value of Gleason Score in Predicting the Benefit of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. Future Oncology. 9:889-897. 2013
- A Comparison of Patient Knowledge of Clinical Trials and Trialist Priorities. Current Oncology. 20:193-205. 2013
- Intraoperative Sonographically Assisted Radioactive Iodine 125 Plaque Brachytherapy for Choroidal Melanoma. Journal of Ultrasound in Medicine. 32:995-1001. 2013
- First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 31:2505-2505. 2013
- Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.. Journal of Clinical Oncology. 31:4539-4539. 2013
- Impact of wait times on survival of women with uterine cancer.. Journal of Clinical Oncology. 31:5586-5586. 2013
- Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 31:4524-4524. 2013
- Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.. Journal of Clinical Oncology. 31:574-574. 2013
- Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.. Journal of Clinical Oncology. 31:10029-10029. 2013
- Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. British Journal of Cancer. 108:2021-2032. 2013
- Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. European Urology. 63:717-723. 2013
- Influence of statistician involvement on reporting of randomized clinical trials in medical oncology. Anti-Cancer Drugs. 24:306-309. 2013
- Cardiac and Inflammation Biomarker Profile after Initiation of Adjuvant Trastuzumab Therapy. Clinical Chemistry. 59:327-329. 2013
- Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Journal of the Canadian Urological Association. 7:74-74. 2013
- A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases. Radiation Oncology. 7:42. 2012
- A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy. BMC Medical Genomics. 5:16. 2012
- Ability of C‐reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel‐based chemotherapy. BJU International. 110:E461-E468. 2012
- Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 10:239-245. 2012
- A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment. 136:143-151. 2012
- Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. Annals of Oncology. 23:2977-2982. 2012
- Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods.. Annals of Oncology. 23:2977-2982. 2012
- Do High Symptom Scores Trigger Clinical Actions? An Audit After Implementing Electronic Symptom Screening. JCO Oncology Practice. 8:e142-e148. 2012
- Enregistrement et publication du critère d’évaluation principal dans les essais contrôlés randomisés en oncologie. Bulletin du Cancer. 99:943-952. 2012
- Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer. Annals of Oncology. 23:ix297-ix298. 2012
- Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis. Palliative Medicine. 26:797-803. 2012
- Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor. Annals of Oncology. 23:ix265-ix266. 2012
- Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic Oncology: Seminars and Original Investigations. 30:607-613. 2012
- Quality of Reporting of Modern Randomized Controlled Trials in Medical Oncology: A Systematic Review. Journal of the National Cancer Institute. 104:982-989. 2012
- Fertility Risk Discussions in Young Patients Diagnosed with Colorectal Cancer. Current Oncology. 19:155-159. 2012
- Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials. Annals of Oncology. 23:1633-1639. 2012
- P-0215 Patient Factors Involved in Referral for Lynch Syndrome. Annals of Oncology. 23:iv91-iv91. 2012
- Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study.. Journal of Clinical Oncology. 30:9021-9021. 2012
- Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort.. Journal of Clinical Oncology. 30:5587-5587. 2012
- Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.. Journal of Clinical Oncology. 30:4644-4644. 2012
- Quantitative immunohistochemical (IHC) assessment of ataxia-telangiectasia mutated (ATM) in estrogen receptor (ER) negative early breast cancer (BC).. Journal of Clinical Oncology. 30:e21083-e21083. 2012
- Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.. Journal of Clinical Oncology. 30:4522-4522. 2012
- Reply to M. Jefford et al and C.T. Stricker et al. Journal of Clinical Oncology. 30:1393-1394. 2012
- Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer. Journal of the National Cancer Institute. 104:590-598. 2012
- The Impact of Chemotherapy-Induced Cognitive Impairment on the Psychosocial Adjustment of Patients With Nonmetastatic Colorectal Cancer. Clinical Journal of Oncology Nursing. 16:163-169. 2012
- 357 Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors. European Journal of Cancer. 48:S147-S147. 2012
- Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. European Urology. 61:363-369. 2012
- Reply to YiJun Shen and DingWei Ye's Letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. Eur Urol 2012;61:363–9. European Urology. 61:e4-e5. 2012
- Statistical and analytical approaches for assessing biomarkers: New approaches, new technologies, with the same-old rigor for evaluation. Clinical Biochemistry. 45:187-188. 2012
- Consistency in the Analysis and Reporting of Primary End Points in Oncology Randomized Controlled Trials From Registration to Publication: A Systematic Review. Journal of Clinical Oncology. 30:210-216. 2012
- Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer. Journal of Clinical Oncology. 29:4755-4762. 2011
- A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials. BMC Medical Research Methodology. 11:95. 2011
- Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials. BMC Medical Research Methodology. 11:164. 2011
- Early stopping rules in oncology: Considerations for clinicians. European Journal of Cancer. 47:2381-2386. 2011
- The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy. Cancer. 117:3963-3971. 2011
- Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials. Clinical Trials. 8:260-269. 2011
- Frequency of fertility discussions among young patients diagnosed with colorectal cancer.. Journal of Clinical Oncology. 29:e19735-e19735. 2011
- Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).. Journal of Clinical Oncology. 29:5522-5522. 2011
- Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors.. Journal of Clinical Oncology. 29:9005-9005. 2011
- Statistical issues in the use of dynamic allocation methods for balancing baseline covariates. British Journal of Cancer. 104:1711-1715. 2011
- Non–Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital’s Experience. European Urology. 59:556-562. 2011
- Multidisciplinary Health Care Professionals' Perceptions of the Use and Utility of a Symptom Assessment System for Oncology Patients. JCO Oncology Practice. 7:19-23. 2011
- Reply to D.J. Stewart. Journal of Clinical Oncology. 28:e651-e651. 2010
- The unclear zone in phase II clinical trials. European Journal of Cancer. 46:2408-2413. 2010
- The Contents and Readability of Informed Consent Forms for Oncology Clinical Trials. American Journal of Clinical Oncology. 33:387-392. 2010
- A Phase III Randomized Trial of the Timing of Meloxicam With Iodine-125 Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics. 77:496-501. 2010
- Expression of EGFR, HER-2/neu and KIT in germ cell tumours. Clinical and Translational Oncology. 12:443-449. 2010
- Trends in the application of dynamic allocation methods in multi-arm cancer clinical trials. Clinical Trials. 7:227-234. 2010
- Randomized Phase II Trials: Inevitable or Inadvisable?. Journal of Clinical Oncology. 28:2641-2647. 2010
- Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 37:88-97. 2010
- Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. Annals of Oncology. 21:19-26. 2010
- Examining the safety and efficacy of a chemotherapy dosing method in Allogeneic Stem Cell Transplant patients of extreme body size. Journal of Oncology Pharmacy Practice. 15:201-210. 2009
- A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium. Journal of Thoracic Oncology. 4:1163-1169. 2009
- Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head and Neck. 31:1006-1012. 2009
- Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies. Journal of Clinical Oncology. 27:e17515-e17515. 2009
- Trends in the application of dynamic allocation methods in multiarm cancer clinical trials. Journal of Clinical Oncology. 27:6550-6550. 2009
- The effect of obesity on rectal dosimetry after permanent prostate brachytherapy. Brachytherapy. 8:218-222. 2009
- Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head and Neck. 30:1607-1614. 2008
- Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer. 8:43. 2008
- Improving Observer Variability in Target Delineation for Gastro-oesophageal Cancer—the Role of 18Ffluoro-2-deoxy-d-glucose Positron Emission Tomography/Computed Tomography. Clinical Oncology. 20:631-638. 2008
- Medication Reconciliation at Hospital Discharge: Evaluating Discrepancies. Annals of Pharmacotherapy. 42:1373-1379. 2008
- Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Annals of Oncology. 19:1749-1753. 2008
- The use and toxicity of steroids in the management of patients with brain metastases. Supportive Care in Cancer. 16:1041-1048. 2008
- Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma. Transplantation and Cellular Therapy. 14:775-782. 2008
- Adherence to Surveillance Guidelines After Curative Resection for Stage II/III Colorectal Cancer. Clinical Colorectal Cancer. 7:191-196. 2008
- Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study. Clinical Cancer Research. 14:2763-2767. 2008
- A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Investigational New Drugs. 26:193-194. 2008
- Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer. 112:1513-1521. 2008
- Improving the Quality of Abstract Reporting for Phase I Cancer Trials. Clinical Cancer Research. 14:1782-1787. 2008
- Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents. Journal of Clinical Oncology. 26:1324-1330. 2008
- A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Research and Treatment. 108:87-92. 2008
- Neuroendocrine Tumors of the Gastrointestinal Tract. American Journal of Clinical Oncology. 31:64-70. 2008
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study. Journal of Clinical Oncology. 26:242-245. 2008
- Long-Term Urinary Sequelae Following ¹²⁵ Iodine Prostate Brachytherapy. Investigative Urology. 179:141-146. 2008
- A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Investigational New Drugs. 25:553-558. 2007
- Role of Fractionated External Beam Radiotherapy in Hemangioblastoma of the Central Nervous System. International Journal of Radiation Oncology Biology Physics. 69:1521-1526. 2007
- The Influence of Mentorship on Research Productivity in Oncology. American Journal of Clinical Oncology. 30:549-555. 2007
- Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer. 110:1307-1312. 2007
- MP-21.03: Penile brachytherapy: results for 60 patients. Urology. 70:161-161. 2007
- POS-03.95: Long-term urinary sequellae following iodine 125 prostate brachytherapy. Urology. 70:302-302. 2007
- POS-03.96: The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Urology. 70:302-302. 2007
- Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. Journal of Clinical Oncology. 25:3978-3984. 2007
- Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 13:4849-4857. 2007
- Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007.. Canadian Journal of Surgery. 50:1-32. 2007
- P2-165: A phase I/II study of concurrent pemetrexed/cisplatin/radiation in stage IIIa/b non-small cell lung cancer. Journal of Thoracic Oncology. 2:S635-S635. 2007
- UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium. Gynecologic Oncology. 106:305-310. 2007
- A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. European Journal of Cancer Care. 16:380-386. 2007
- Intraobserver and Interobserver Variability in GTV Delineation on FDG-PET-CT Images of Head and Neck Cancers. International Journal of Radiation Oncology Biology Physics. 68:763-770. 2007
- The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. Supportive Care in Cancer. 15:829-840. 2007
- The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Brachytherapy. 6:173-179. 2007
- A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 25:3576-3576. 2007
- A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens. Journal of Clinical Oncology. 25:6569-6569. 2007
- A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors. Journal of Clinical Oncology. 25:14030-14030. 2007
- Adherence to surveillance guidelines following curative resection for stage II and III colorectal cancer. Journal of Clinical Oncology. 25:4051-4051. 2007
- CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib—A trial of the PMH Phase II Consortium. Journal of Clinical Oncology. 25:5519-5519. 2007
- Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC). Journal of Clinical Oncology. 25:9099-9099. 2007
- Correlation between changes in 2- or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966–2006. Journal of Clinical Oncology. 25:581-581. 2007
- Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. Journal of Clinical Oncology. 25:9070-9070. 2007
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study. Journal of Clinical Oncology. 25:5005-5005. 2007
- Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). Journal of Clinical Oncology. 25:5021-5021. 2007
- Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs). Journal of Clinical Oncology. 25:6601-6601. 2007
- The quality of phase I trial (P1T) abstracts submitted to ASCO meetings. Journal of Clinical Oncology. 25:6532-6532. 2007
- Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. Journal of Clinical Oncology. 25:2184-2190. 2007
- A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Investigational New Drugs. 25:181-185. 2007
- Penile brachytherapy: Results for 60 patients. Brachytherapy. 6:82-82. 2007
- The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Brachytherapy. 6:105-105. 2007
- Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study. International Journal of Radiation Oncology Biology Physics. 67:1027-1036. 2007
- A feasibility study of an internal control methodology using hydrocortisone cream for the management of skin reactions in patients receiving radical radiation therapy for cancers of the head and neck. Journal of Radiotherapy in Practice. 5:211-218. 2006
- Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer. 6:263. 2006
- Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer. 6:34. 2006
- Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. European Journal of Cancer. 42:1875-1880. 2006
- Computerized tomographic simulation compared with clinical mark-up in palliative radiotherapy: A prospective study. International Journal of Radiation Oncology Biology Physics. 65:824-829. 2006
- Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography. International Journal of Radiation Oncology Biology Physics. 65:688-693. 2006
- A phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM-h-R3 (nimotuzumab) in patients with advanced solid tumors. Journal of Clinical Oncology. 24:13054-13054. 2006
- A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798. Journal of Clinical Oncology. 24:14072-14072. 2006
- A randomized controlled trial to evaluate the impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. Journal of Clinical Oncology. 24:6011-6011. 2006
- Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. Journal of Clinical Oncology. 24:4516-4516. 2006
- Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. Journal of Clinical Oncology. 24:8501-8501. 2006
- Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function. Journal of Clinical Oncology. 24:3623-3623. 2006
- Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer. Journal of Clinical Oncology. 24:4101-4101. 2006
- Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital. Journal of Clinical Oncology. 24:4093-4093. 2006
- Phase II study of sorafenib (BAY 43–9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. Journal of Clinical Oncology. 24:5084-5084. 2006
- Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study. Journal of Clinical Oncology. 24:4557-4557. 2006
- Natural History and Chemotherapy Effectiveness for Advanced Adenocarcinoma of the Small Bowel: A Retrospective Review of 113 Cases. American Journal of Clinical Oncology. 29:225-231. 2006
- Natural History and Chemotherapy Effectiveness for Advanced Adenocarcinoma of the Small Bowel: A Retrospective Review of 113 Cases. American Journal of Clinical Oncology. 29:225-231. 2006
- Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer. 52:327-332. 2006
- Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. International Journal of Radiation Oncology Biology Physics. 65:358-363. 2006
- Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination. Clinical Cancer Research. 12:2141-2149. 2006
- Long-Term Survival after Blood and Marrow Transplantation: Comparison with an Age- and Gender-Matched Normative Population. Transplantation and Cellular Therapy. 12:422-429. 2006
- Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.. Canadian Journal of Urology. 13 Suppl 2:2-10. 2006
- Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. British Journal of Cancer. 94:1136-1143. 2006
- Radiation dose to the internal pudendal arteries from permanent seed prostate brachytherapy as determined by time-of-flight angiography. Brachytherapy. 5:78-78. 2006
- Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. British Journal of Cancer. 94:1011-1015. 2006
- Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. International Journal of Radiation Oncology Biology Physics. 64:709-716. 2006
- Identification of Small Molecules that Sensitize Resistant Tumor Cells to Tumor Necrosis Factor-Family Death Receptors. Cancer Research. 66:2367-2375. 2006
- Making Sense of Prostate Specific Antigen: Improving its Predictive Value in Patients Undergoing Prostate Biopsy. Investigative Urology. 175:489-494. 2006
- Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Annals of Oncology. 17:334-340. 2006
- Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. Anti-Cancer Drugs. 17:81-87. 2006
- Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy. 5:9-13. 2006
- A Multicenter Phase II Study of “Adjuvant” Irinotecan Following Resection of Colorectal Hepatic Metastases. American Journal of Clinical Oncology. 28:547-554. 2005
- Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia. Apoptosis : an international journal on programmed cell death. 10:1285-1294. 2005
- Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation. Mayo Clinic proceedings. 80:1578-1582. 2005
- Radiation therapy for Bowen’s disease of the skin. International Journal of Radiation Oncology Biology Physics. 63:505-510. 2005
- Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. International Journal of Gynecological Cancer. 15:799-806. 2005
- Factors Influencing the Use of Single vs Multiple Fractions of Palliative Radiotherapy for Bone Metastases: A 5-Year Review. Clinical Oncology. 17:430-434. 2005
- P-526 Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 49:S255-S256. 2005
- Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion. International Journal of Radiation Oncology Biology Physics. 62:974-980. 2005
- A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). Journal of Clinical Oncology. 23:5566-5566. 2005
- A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs). Journal of Clinical Oncology. 23:3096-3096. 2005
- Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada. Journal of Clinical Oncology. 23:3802-3810. 2005
- Penile brachytherapy: Results for 49 patients. International Journal of Radiation Oncology Biology Physics. 62:460-467. 2005
- Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors. Journal of Clinical Oncology. 23:7253-7253. 2005
- Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium. Journal of Clinical Oncology. 23:4677-4677. 2005
- Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib. Journal of Clinical Oncology. 23:9618-9618. 2005
- The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents. Journal of Clinical Oncology. 23:6006-6006. 2005
- Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual. Journal of Clinical Oncology. 23:8245-8245. 2005
- Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 105:4043-4050. 2005
- Posttreatment Complications of Early-Stage Prostate Cancer Patients. Cancer Journal. 11:122-132. 2005
- Assessing perfusion changes during whole brain irradiation for patients with cerebral metastases. Journal of Neuro-Oncology. 71:281-286. 2005
- Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study. Journal of Clinical Oncology. 23:585-590. 2005
- Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplantation. 35:51-55. 2005
- Weekly Cyclophosphamide and Alternate Day Prednisone: An Effective, Convenient and Well Tolerated Treatment for Relapsed Multiple Myeloma Following Autologous Stem Cell Transplant.. Blood. 104:4917-4917. 2004
- Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. International Journal of Radiation Oncology Biology Physics. 60:1127-1136. 2004
- 408 A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL-002e/NCIC CTG IND.157). European Journal of Cancer, Supplement. 2:122-122. 2004
- Sequential evaluation of prostate edema following permanent seed prostate brachytherapy using CT-MRI fusion. International Journal of Radiation Oncology Biology Physics. 60:S456-S456. 2004
- Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy?. Clinical Oncology. 16:332-338. 2004
- Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens. Journal of Clinical Oncology. 22:6000-6000. 2004
- Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens. Journal of Clinical Oncology. 22:6000-6000. 2004
- Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada. Journal of Clinical Oncology. 22:8168-8168. 2004
- Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada. Journal of Clinical Oncology. 22:8168-8168. 2004
- Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Journal of Clinical Oncology. 22:5572-5572. 2004
- Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Journal of Clinical Oncology. 22:5572-5572. 2004
- Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Annals of Oncology. 15:770-774. 2004
- Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction. American Journal of Pathology. 164:285-293. 2004
- Measured and estimated GFR in healthy potential kidney donors. American Journal of Kidney Diseases. 43:112-119. 2004
- 191 Phase II trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer. European Journal of Cancer, Supplement. 1:S60-S61. 2003
- A Phase I Study of Pegylated Liposomal Doxorubicin Hydrochloride (Caelyx™) in Combination with Cyclophosphamide and Vincristine as Second-Line Treatment of Patients with Small-Cell Lung Cancer. Clinical Lung Cancer. 5:107-112. 2003
- Phase II study of pegylated liposomal doxorubicin HCI (caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer. 41:S232-S232. 2003
- Speech Recognition as a Transcription Aid: A Randomized Comparison With Standard Transcription. Journal of the American Medical Informatics Association : JAMIA. 10:85-93. 2003
- Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer. 11:41-47. 2003
- Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer. 95:2516-2523. 2002
- ???PSA-itis???: Knowledge of Serum Prostate Specific Antigen and Other Causes of Anxiety in Men with Metastatic Prostate Cancer. Investigative Urology. 168:2516-2520. 2002
- Ethical communication in clinical trials. Cancer. 95:2414-2421. 2002
- “PSA-itis”: Knowledge of Serum Prostate Specific Antigen and Other Causes of Anxiety in Men with Metastatic Prostate Cancer. Investigative Urology. 168:2516-2520. 2002
- Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based study. Arthritis and Rheumatism. 46:2287-2293. 2002
- Predictors of infection in rheumatoid arthritis. Arthritis and Rheumatism. 46:2294-2300. 2002
- Prognostic factors for life expectancy in nonagenarians with nonmelanoma skin cancer: Implications for selecting surgical candidates. Journal of American Academy of Dermatology. 47:419-422. 2002
- The Decision to Accept Treatment for Osteoporosis Following Hip Fracture: Exploring the Woman’s Perspective Using a Stage-of-Change Model. Osteoporosis International. 13:560-564. 2002
- The Position of the Polycystic Kidney Disease 1 (PKD1) Gene Mutation Correlates with the Severity of Renal Disease. Journal of the American Society of Nephrology. 13:1230-1237. 2002
- Direct Medical Costs Attributable to Osteoporotic Fractures. Osteoporosis International. 13:323-330. 2002
- Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty‐year period. Arthritis and Rheumatism. 46:625-631. 2002
- Dermopathy of Graves' Disease (Pretibial Myxedema): Long-Term Outcome. Journal of Clinical Endocrinology and Metabolism (JCEM). 87:438-446. 2002
- Dermopathy of Graves’ Disease (Pretibial Myxedema): Long-Term Outcome. Journal of Clinical Endocrinology and Metabolism (JCEM). 87:438-446. 2002
- The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy. Brachytherapy. 1:131-137. 2002
- Applications: Estimation of the Magnitude of Victory in One‐day Cricket RMIT University, Mayo Clinic Rochester and Simon Fraser University. Australian and New Zealand Journal of Statistics. 43:259-268. 2001
- Treating Fibromyalgia With a Brief Interdisciplinary Program: Initial Outcomes and Predictors of Response. Mayo Clinic proceedings. 76:384-390. 2001
- Treating Fibromyalgia With a Brief Interdisciplinary Program: Initial Outcomes and Predictors of Response. Mayo Clinic proceedings. 76:384-390. 2001
- Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre. Genetic Syndromes and Gene Therapy. 04.
- Teaching Residents how to Effectively Prescribe Nicotine Replacement Therapy on the Clinical Teaching Unit. Canadian Journal of General Internal Medicine. 13:e17-e20.
preprints